{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T17:49:27Z","timestamp":1789321767573,"version":"build-2803163510"},"reference-count":328,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/Y008138\/1"],"award-info":[{"award-number":["MR\/Y008138\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Mechanistic target of rapamycin (mTOR) is a highly conserved serine\/threonine kinase that regulates key cellular processes including cell growth, autophagy and metabolism. Hyperactivation of the mTOR pathway causes a group of rare and ultrarare genetic diseases. mTOR pathway diseases have diverse clinical manifestations that are managed by distinct medical disciplines but share a common underlying molecular basis. There is a now a deep understanding of the molecular underpinning that regulates the mTOR pathway but effective treatments for most mTOR pathway diseases are lacking. Translating scientific knowledge into clinical applications to benefit the unmet clinical needs of patients is a major challenge common to many rare diseases. In this article we expound how mTOR pathway diseases provide an opportunity to coordinate basic and translational disease research across the group, together with industry, medical research foundations, charities and patient groups, by pooling expertise and driving progress to benefit patients. We outline the germline and somatic mutations in the mTOR pathway that cause rare diseases and summarise the prevalence, genetic basis, clinical manifestations, pathophysiology and current treatments for each disease in this group. We describe the challenges and opportunities for progress in elucidating the underlying mechanisms, improving diagnosis and prognosis, as well as the development and approval of new therapies for mTOR pathway diseases. We illustrate the crucial role of patient public involvement and engagement in rare disease and mTOR pathway disease research. Finally, we explain how the mTOR Pathway Diseases node, part of the Research Disease Research UK Platform, will address these challenges to improve the understanding, diagnosis and treatment of mTOR pathway diseases.<\/jats:p>","DOI":"10.1186\/s13023-025-03740-1","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T05:50:42Z","timestamp":1748325042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node"],"prefix":"10.1186","volume":"20","author":[{"given":"Laura","family":"Mantoan Ritter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M. P.","family":"Annear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Baple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila Y.","family":"Ben-Chaabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Bodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Brosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill E.","family":"Cadwgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryn","family":"Coslett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Crosby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Mark","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Daykin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Dedeurwaerdere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"D\u00fchring Fenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A.","family":"Dunlop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances V.","family":"Elmslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Girodengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hambleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna C.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly C.","family":"Kearley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Kingswood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisi","family":"Laaniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Lachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Latchford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralitsa R.","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon R.","family":"Mihaylov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louwai","family":"Muhammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Pepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lettie E.","family":"Rawlins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Schim van der Loeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ata","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Takhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Tatton-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Tibarewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Tye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sila K.","family":"Ultanir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Vanhaesebroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deb K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0754-1785","authenticated-orcid":false,"given":"Joseph M.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"11","key":"3740_CR1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/d41573-023-00145-2","volume":"22","author":"DJ O'Connor","year":"2023","unstructured":"O\u2019Connor DJ, Gabaldo M, Aartsma-Rus A, Hechtelt JA. Defining rare conditions in the era of personalized medicine. Nat Rev Drug Discov. 2023;22(11):857\u20138.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"3740_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165\u201373.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"3740_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-023-02790-7","volume":"18","author":"LJ Fermaglich","year":"2023","unstructured":"Fermaglich LJ, Miller KL. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet J Rare Dis. 2023;18(1):163.","journal-title":"Orphanet J Rare Dis"},{"key":"3740_CR4","unstructured":"UK Rare Diseases Framework [Available from: https:\/\/www.gov.uk\/government\/publications\/uk-rare-diseases-framework. Accessed on 30th Sept 2024"},{"key":"3740_CR5","unstructured":"mTOR Pathway Diseases [Available from: https:\/\/rd-research.org.uk\/node\/mtor-pathway-diseases\/. Accessed on 30th Sept 2024"},{"key":"3740_CR6","unstructured":"Rare Disease Research UK Platform [Available from: https:\/\/rd-research.org.uk\/platform\/. Accessed on 30th Sept 2024"},{"issue":"5022","key":"3740_CR7","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1126\/science.1715094","volume":"253","author":"J Heitman","year":"1991","unstructured":"Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253(5022):905\u20139.","journal-title":"Science"},{"issue":"10","key":"3740_CR8","first-page":"6012","volume":"13","author":"R Cafferkey","year":"1993","unstructured":"Cafferkey R, Young PR, McLaughlin MM, Bergsma DJ, Koltin Y, Sathe GM, et al. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol. 1993;13(10):6012\u201323.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"3740_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0092-8674(93)90144-F","volume":"73","author":"J Kunz","year":"1993","unstructured":"Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 1993;73(3):585\u201396.","journal-title":"Cell"},{"issue":"1","key":"3740_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1091\/mbc.5.1.105","volume":"5","author":"SB Helliwell","year":"1994","unstructured":"Helliwell SB, Wagner P, Kunz J, Deuter-Reinhard M, Henriquez R, Hall MN. TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol Biol Cell. 1994;5(1):105\u201318.","journal-title":"Mol Biol Cell"},{"issue":"4","key":"3740_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","volume":"21","author":"GY Liu","year":"2020","unstructured":"Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol. 2020;21(4):183\u2013203.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3740_CR12","doi-asserted-by":"publisher","first-page":"1005631","DOI":"10.3389\/fnmol.2022.1005631","volume":"15","author":"M Girodengo","year":"2022","unstructured":"Girodengo M, Ultanir SK, Bateman JM. Mechanistic target of rapamycin signaling in human nervous system development and disease. Front Mol Neurosci. 2022;15:1005631.","journal-title":"Front Mol Neurosci"},{"issue":"7448","key":"3740_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature12122","volume":"497","author":"H Yang","year":"2013","unstructured":"Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature. 2013;497(7448):217\u201323.","journal-title":"Nature"},{"issue":"6268","key":"3740_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1126\/science.aaa3870","volume":"351","author":"CH Aylett","year":"2016","unstructured":"Aylett CH, Sauer E, Imseng S, Boehringer D, Hall MN, Ban N, et al. Architecture of human mTOR complex 1. Science. 2016;351(6268):48\u201352.","journal-title":"Science"},{"issue":"2","key":"3740_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","volume":"110","author":"DH Kim","year":"2002","unstructured":"Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110(2):163\u201375.","journal-title":"Cell"},{"issue":"4","key":"3740_CR16","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1097-2765(03)00114-X","volume":"11","author":"DH Kim","year":"2003","unstructured":"Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell. 2003;11(4):895\u2013904.","journal-title":"Mol Cell"},{"issue":"6","key":"3740_CR17","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.devcel.2006.10.007","volume":"11","author":"DA Guertin","year":"2006","unstructured":"Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006;11(6):859\u201371.","journal-title":"Dev Cell"},{"issue":"12","key":"3740_CR18","doi-asserted-by":"publisher","first-page":"E1453","DOI":"10.1152\/ajpendo.00660.2011","volume":"302","author":"C Wiza","year":"2012","unstructured":"Wiza C, Nascimento EB, Ouwens DM. Role of PRAS40 in Akt and mTOR signaling in health and disease. Am J Physiol Endocrinol Metab. 2012;302(12):E1453\u201360.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"3740_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2009.03.046","volume":"137","author":"TR Peterson","year":"2009","unstructured":"Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137(5):873\u201386.","journal-title":"Cell"},{"issue":"45","key":"3740_CR20","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.0809136105","volume":"105","author":"AY Choo","year":"2008","unstructured":"Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A. 2008;105(45):17414\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"3740_CR21","doi-asserted-by":"publisher","first-page":"102288","DOI":"10.1016\/j.jbc.2022.102288","volume":"298","author":"Z Yu","year":"2022","unstructured":"Yu Z, Chen J, Takagi E, Wang F, Saha B, Liu X, et al. Interactions between mTORC2 core subunits Rictor and mSin1 dictate selective and context-dependent phosphorylation of substrate kinases SGK1 and Akt. J Biol Chem. 2022;298(9):102288.","journal-title":"J Biol Chem"},{"issue":"5","key":"3740_CR22","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41422-018-0029-3","volume":"28","author":"X Chen","year":"2018","unstructured":"Chen X, Liu M, Tian Y, Li J, Qi Y, Zhao D, et al. Cryo-EM structure of human mTOR complex 2. Cell Res. 2018;28(5):518\u201328.","journal-title":"Cell Res"},{"issue":"3","key":"3740_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1042\/BJ20070540","volume":"405","author":"LR Pearce","year":"2007","unstructured":"Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M, et al. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J. 2007;405(3):513\u201322.","journal-title":"Biochem J"},{"issue":"1","key":"3740_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1042\/BJ20102103","volume":"436","author":"LR Pearce","year":"2011","unstructured":"Pearce LR, Sommer EM, Sakamoto K, Wullschleger S, Alessi DR. Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem J. 2011;436(1):169\u201379.","journal-title":"Biochem J"},{"issue":"2","key":"3740_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.molcel.2008.03.003","volume":"30","author":"DM Gwinn","year":"2008","unstructured":"Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30(2):214\u201326.","journal-title":"Mol Cell"},{"issue":"5960","key":"3740_CR26","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1126\/science.1178377","volume":"326","author":"E Zeqiraj","year":"2009","unstructured":"Zeqiraj E, Filippi BM, Deak M, Alessi DR, van Aalten DM. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science. 2009;326(5960):1707\u201311.","journal-title":"Science"},{"issue":"6136","key":"3740_CR27","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1126\/science.1232044","volume":"340","author":"L Bar-Peled","year":"2013","unstructured":"Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, et al. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science. 2013;340(6136):1100\u20136.","journal-title":"Science"},{"issue":"7919","key":"3740_CR28","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41586-022-04939-z","volume":"607","author":"ML Valenstein","year":"2022","unstructured":"Valenstein ML, Rogala KB, Lalgudi PV, Brignole EJ, Gu X, Saxton RA, et al. Structure of the nutrient-sensing hub GATOR2. Nature. 2022;607(7919):610\u20136.","journal-title":"Nature"},{"key":"3740_CR29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3389\/fcell.2020.00715","volume":"8","author":"M Kitada","year":"2020","unstructured":"Kitada M, Xu J, Ogura Y, Monno I, Koya D. Mechanism of activation of mechanistic target of rapamycin complex 1 by methionine. Front Cell Dev Biol. 2020;8:715.","journal-title":"Front Cell Dev Biol"},{"issue":"7645","key":"3740_CR30","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nature21423","volume":"543","author":"RL Wolfson","year":"2017","unstructured":"Wolfson RL, Chantranupong L, Wyant GA, Gu X, Orozco JM, Shen K, et al. KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1. Nature. 2017;543(7645):438\u201342.","journal-title":"Nature"},{"issue":"4","key":"3740_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.molcel.2013.09.016","volume":"52","author":"ZY Tsun","year":"2013","unstructured":"Tsun ZY, Bar-Peled L, Chantranupong L, Zoncu R, Wang T, Kim C, et al. The folliculin tumor suppressor is a GAP for the RagC\/D GTPases that signal amino acid levels to mTORC1. Mol Cell. 2013;52(4):495\u2013505.","journal-title":"Mol Cell"},{"issue":"3","key":"3740_CR32","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s42255-019-0038-7","volume":"1","author":"AJ Valvezan","year":"2019","unstructured":"Valvezan AJ, Manning BD. Molecular logic of mTORC1 signalling as a metabolic rheostat. Nat Metab. 2019;1(3):321\u201333.","journal-title":"Nat Metab"},{"key":"3740_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev-immunol-020711-075024","volume":"30","author":"JD Powell","year":"2012","unstructured":"Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30:39\u201368.","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"3740_CR34","doi-asserted-by":"publisher","first-page":"e1004624","DOI":"10.1371\/journal.pgen.1004624","volume":"10","author":"A Avet-Rochex","year":"2014","unstructured":"Avet-Rochex A, Carvajal N, Christoforou CP, Yeung K, Maierbrugger KT, Hobbs C, et al. Unkempt is negatively regulated by mTOR and uncouples neuronal differentiation from growth control. PLoS Genet. 2014;10(9):e1004624.","journal-title":"PLoS Genet"},{"issue":"1","key":"3740_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cell.2004.08.028","volume":"119","author":"J Bateman","year":"2004","unstructured":"Bateman J, McNeill H. Temporal control of differentiation by the insulin receptor\/Tor pathway in Drosophila. Cell. 2004;119(1):87\u201396.","journal-title":"Cell"},{"issue":"1","key":"3740_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ydbio.2020.01.006","volume":"461","author":"KT Maierbrugger","year":"2020","unstructured":"Maierbrugger KT, Sousa-Nunes R, Bateman JM. The mTOR pathway component Unkempt regulates neural stem cell and neural progenitor cell cycle in the Drosophila central nervous system. Dev Biol. 2020;461(1):55\u201365.","journal-title":"Dev Biol"},{"issue":"1","key":"3740_CR37","doi-asserted-by":"publisher","first-page":"16299","DOI":"10.1038\/s41598-021-95286-y","volume":"11","author":"E Vinsland","year":"2021","unstructured":"Vinsland E, Baskaran P, Mihaylov SR, Hobbs C, Wood H, Bouybayoune I, et al. The zinc finger\/RING domain protein Unkempt regulates cognitive flexibility. Sci Rep. 2021;11(1):16299.","journal-title":"Sci Rep"},{"key":"3740_CR38","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1146\/annurev-immunol-032712-095946","volume":"31","author":"K Okkenhaug","year":"2013","unstructured":"Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol. 2013;31:675\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"3740_CR39","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41580-019-0129-z","volume":"20","author":"B Bilanges","year":"2019","unstructured":"Bilanges B, Posor Y, Vanhaesebroeck B. PI3K isoforms in cell signalling and vesicle trafficking. Nat Rev Mol Cell Biol. 2019;20(9):515\u201334.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"3740_CR40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri.2016.93","volume":"16","author":"CL Lucas","year":"2016","unstructured":"Lucas CL, Chandra A, Nejentsev S, Condliffe AM, Okkenhaug K. PI3K\u03b4 and primary immunodeficiencies. Nat Rev Immunol. 2016;16(11):702\u201314.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"3740_CR41","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.jaci.2018.06.039","volume":"142","author":"G Sogkas","year":"2018","unstructured":"Sogkas G, Fedchenko M, Dhingra A, Jablonka A, Schmidt RE, Atschekzei F. Primary immunodeficiency disorder caused by phosphoinositide 3-kinase \u03b4 deficiency. J Allergy Clin Immunol. 2018;142(5):1650-3.e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3740_CR42","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jaci.2018.10.005","volume":"143","author":"SB Cohen","year":"2019","unstructured":"Cohen SB, Bainter W, Johnson JL, Lin TY, Wong JCY, Wallace JG, et al. Human primary immunodeficiency caused by expression of a kinase-dead p110\u03b4 mutant. J Allergy Clin Immunol. 2019;143(2):797-9.e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"3740_CR43","doi-asserted-by":"publisher","first-page":"e483","DOI":"10.3324\/haematol.2018.208397","volume":"104","author":"DJ Swan","year":"2019","unstructured":"Swan DJ, Aschenbrenner D, Lamb CA, Chakraborty K, Clark J, Pandey S, et al. Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase \u03b4. Haematologica. 2019;104(10):e483\u20136.","journal-title":"Haematologica"},{"issue":"3","key":"3740_CR44","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1084\/jem.20112533","volume":"209","author":"ME Conley","year":"2012","unstructured":"Conley ME, Dobbs AK, Quintana AM, Bosompem A, Wang YD, Coustan-Smith E, et al. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85\u03b1 subunit of PI3K. J Exp Med. 2012;209(3):463\u201370.","journal-title":"J Exp Med"},{"issue":"6160","key":"3740_CR45","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1126\/science.1243292","volume":"342","author":"I Angulo","year":"2013","unstructured":"Angulo I, Vadas O, Gar\u00e7on F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866\u201371.","journal-title":"Science"},{"issue":"1","key":"3740_CR46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","volume":"15","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88\u201397.","journal-title":"Nat Immunol"},{"issue":"13","key":"3740_CR47","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1084\/jem.20141759","volume":"211","author":"CL Lucas","year":"2014","unstructured":"Lucas CL, Zhang Y, Venida A, Wang Y, Hughes J, McElwee J, et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med. 2014;211(13):2537\u201347.","journal-title":"J Exp Med"},{"issue":"9","key":"3740_CR48","doi-asserted-by":"publisher","first-page":"3923","DOI":"10.1172\/JCI75746","volume":"124","author":"MC Deau","year":"2014","unstructured":"Deau MC, Heurtier L, Frange P, Suarez F, Bole-Feysot C, Nitschke P, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2014;124(9):3923\u20138.","journal-title":"J Clin Invest"},{"key":"3740_CR49","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fimmu.2018.00543","volume":"9","author":"ME Maccari","year":"2018","unstructured":"Maccari ME, Abolhassani H, Aghamohammadi A, Aiuti A, Aleinikova O, Bangs C, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-Kinase \u03b4 Syndrome: the european society for immunodeficiencies-activated phosphoinositide 3-kinase \u03b4 syndrome registry. Front Immunol. 2018;9:543.","journal-title":"Front Immunol"},{"issue":"9","key":"3740_CR50","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2022018546","volume":"141","author":"VK Rao","year":"2023","unstructured":"Rao VK, Webster S, \u0160ediv\u00e1 A, Plebani A, Schuetz C, Shcherbina A, et al. A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome. Blood. 2023;141(9):971\u201383.","journal-title":"Blood"},{"issue":"1","key":"3740_CR51","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jaci.2021.04.036","volume":"149","author":"D Dimitrova","year":"2022","unstructured":"Dimitrova D, Nademi Z, Maccari ME, Ehl S, Uzel G, Tomoda T, et al. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. J Allergy Clin Immunol. 2022;149(1):410-21.e7.","journal-title":"J Allergy Clin Immunol"},{"key":"3740_CR52","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.semcancer.2019.02.001","volume":"59","author":"V \u00c1lvarez-Garcia","year":"2019","unstructured":"\u00c1lvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It\u2019s all about diversity. Semin Cancer Biol. 2019;59:66\u201379.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"3740_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/biom9040153","volume":"9","author":"A Papa","year":"2019","unstructured":"Papa A, Pandolfi PP. The PTEN\u207bPI3K axis in cancer. Biomolecules. 2019;9(4):153.","journal-title":"Biomolecules"},{"issue":"9","key":"3740_CR54","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/s41580-018-0015-0","volume":"19","author":"YR Lee","year":"2018","unstructured":"Lee YR, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol. 2018;19(9):547\u201362.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"3740_CR55","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.molcel.2017.09.024","volume":"68","author":"M Malek","year":"2017","unstructured":"Malek M, Kielkowska A, Chessa T, Anderson KE, Barneda D, Pir P, et al. PTEN Regulates PI(3,4)P(2) signaling downstream of class I PI3K. Mol Cell. 2017;68(3):566-80.e10.","journal-title":"Mol Cell"},{"issue":"1","key":"3740_CR56","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/ng0597-64","volume":"16","author":"D Liaw","year":"1997","unstructured":"Liaw D, Marsh DJ, Li J, Dahia PLM, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997;16(1):64\u20137.","journal-title":"Nat Genet"},{"issue":"4","key":"3740_CR57","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/ng0897-333","volume":"16","author":"DJ Marsh","year":"1997","unstructured":"Marsh DJ, Dahia PLM, Zheng Z, Liaw D, Parsons R, Gorlin RJ, et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet. 1997;16(4):333\u20134.","journal-title":"Nat Genet"},{"issue":"2","key":"3740_CR58","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1086\/377109","volume":"73","author":"X-P Zhou","year":"2003","unstructured":"Zhou X-P, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C, et al. Germline PTEN promoter mutations and deletions in cowden\/bannayan-riley-ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase\/Akt pathway. Am J Human Genet. 2003;73(2):404\u201311.","journal-title":"Am J Human Genet"},{"issue":"2","key":"3740_CR59","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1172\/JCI121277","volume":"129","author":"L Yehia","year":"2019","unstructured":"Yehia L, Ngeow J, Eng C. PTEN-opathies: from biological insights to evidence-based precision medicine. J Clin Investig. 2019;129(2):452\u201364.","journal-title":"J Clin Investig"},{"issue":"9","key":"3740_CR60","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/gim.2012.51","volume":"14","author":"J Mester","year":"2012","unstructured":"Mester J, Eng C. Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genet Med. 2012;14(9):819\u201322.","journal-title":"Genet Med"},{"key":"3740_CR61","doi-asserted-by":"crossref","unstructured":"Hendricks LAJ, Hoogerbrugge N, Venselaar H, Aretz S, Spier I, Legius E, et al. Genotype-phenotype associations in a large PTEN Hamartoma Tumor Syndrome (PHTS) patient cohort. European Journal of Medical Genetics. 2022; 65(12).","DOI":"10.1016\/j.ejmg.2022.104632"},{"issue":"1","key":"3740_CR62","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jnci\/djac188","volume":"115","author":"LAJ Hendricks","year":"2023","unstructured":"Hendricks LAJ, Hoogerbrugge N, Mensenkamp AR, Brunet J, Lleuger-Pujol R, H\u00f8berg-Vetti H, et al. Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome. JNCI J Natl Cancer Inst. 2023;115(1):93\u2013103.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"10","key":"3740_CR63","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/s41431-020-0651-7","volume":"28","author":"M Tischkowitz","year":"2020","unstructured":"Tischkowitz M, Colas C, Pouwels S, Hoogerbrugge N, Bisseling T, Bubien V, et al. Cancer surveillance guideline for individuals with PTEN hamartoma tumour syndrome. Eur J Hum Genet. 2020;28(10):1387\u201393.","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"3740_CR64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.0.CO;2-B","volume":"71","author":"EM Arch","year":"1997","unstructured":"Arch EM, Goodman BK, Van Wesep RA, Liaw D, Clarke K, Parsons R, et al. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. Am J Med Genet. 1997;71(4):489\u201393.","journal-title":"Am J Med Genet"},{"issue":"9","key":"3740_CR65","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1136\/jmg.2007.049981","volume":"44","author":"KL Lachlan","year":"2007","unstructured":"Lachlan KL, Lucassen AM, Bunyan D, Temple IK. Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet. 2007;44(9):579\u201385.","journal-title":"J Med Genet"},{"issue":"8","key":"3740_CR66","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/hmg\/8.8.1461","volume":"8","author":"DJ Marsh","year":"1999","unstructured":"Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, Ahmed SF, et al. PTEN mutation spectrum and genotype-phenotype correlations in bannayan-riley-ruvalcaba syndrome suggest a single entity with cowden syndrome. Hum Mol Genet. 1999;8(8):1461\u201372.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"3740_CR67","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/jmg.40.10.e111","volume":"40","author":"JHM Merks","year":"2003","unstructured":"Merks JHM. PTEN hamartoma tumour syndrome: variability of an entity. J Med Genet. 2003;40(10):111.","journal-title":"J Med Genet"},{"issue":"4","key":"3740_CR68","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/(SICI)1096-8628(19981204)80:4<399::AID-AJMG18>3.0.CO;2-O","volume":"80","author":"RT Zori","year":"1998","unstructured":"Zori RT, Marsh DJ, Graham GE, Marliss EB, Eng C. Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet. 1998;80(4):399\u2013402.","journal-title":"Am J Med Genet"},{"issue":"3","key":"3740_CR69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/sj.ejhg.5200289","volume":"7","author":"MR Nelen","year":"1999","unstructured":"Nelen MR, Kremer H, Konings IB, Schoute F, van Essen AJ, Koch R, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999;7(3):267\u201373.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"3740_CR70","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ajhg.2010.11.013","volume":"88","author":"MH Tan","year":"2011","unstructured":"Tan MH, Mester J, Peterson C, Yang Y, Chen JL, Rybicki LA, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Human Genet. 2011;88(1):42\u201356.","journal-title":"Am J Human Genet"},{"issue":"1","key":"3740_CR71","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jnci\/djac188","volume":"115","author":"LAJ Hendricks","year":"2023","unstructured":"Hendricks LAJ, Hoogerbrugge N, Mensenkamp AR, Brunet J, Lleuger-Pujol R, H\u00f8berg-Vetti H, et al. Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome. J Natl Cancer Inst. 2023;115(1):93\u2013103.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"3740_CR72","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1136\/jmedgenet-2016-104484","volume":"54","author":"E Hansen-Kiss","year":"2017","unstructured":"Hansen-Kiss E, Beinkampen S, Adler B, Frazier T, Prior T, Erdman S, et al. A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children. J Med Genet. 2017;54(7):471\u20138.","journal-title":"J Med Genet"},{"issue":"7","key":"3740_CR73","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/ejhg.2011.20","volume":"19","author":"JL Mester","year":"2011","unstructured":"Mester JL, Tilot AK, Rybicki LA, Frazier TW, Eng C. Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur J Hum Genet. 2011;19(7):763\u20138.","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"3740_CR74","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1136\/jmg.2007.048934","volume":"44","author":"WH Tan","year":"2007","unstructured":"Tan WH, Baris HN, Burrows PE, Robson CD, Alomari AI, Mulliken JB, et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet. 2007;44(9):594\u2013602.","journal-title":"J Med Genet"},{"issue":"6","key":"3740_CR75","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/j.jaci.2016.03.055","volume":"138","author":"Y Tsujita","year":"2016","unstructured":"Tsujita Y, Mitsui-Sekinaka K, Imai K, Yeh TW, Mitsuiki N, Asano T, et al. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase \u03b4 syndrome-like immunodeficiency. J Allergy Clin Immunol. 2016;138(6):1672-80.e10.","journal-title":"J Allergy Clin Immunol"},{"key":"3740_CR76","doi-asserted-by":"publisher","first-page":"702872","DOI":"10.3389\/fped.2021.702872","volume":"9","author":"V Redenbaugh","year":"2021","unstructured":"Redenbaugh V, Coulter T. Disorders related to PI3K\u03b4 hyperactivation: characterizing the clinical and immunological features of activated PI3-kinase delta syndromes. Front Pediatr. 2021;9:702872.","journal-title":"Front Pediatr"},{"key":"3740_CR77","doi-asserted-by":"publisher","first-page":"104960","DOI":"10.1016\/j.ejmg.2024.104960","volume":"70","author":"M Drissen","year":"2024","unstructured":"Drissen M, Vos JR, Collado Camps E, Schuurs-Hoeijmakers JHM, Schieving JH, Hoogerbrugge N. Increased frequency of infections and autoimmune disease in adults with PTEN Hamartoma tumour syndrome. Eur J Med Genet. 2024;70:104960.","journal-title":"Eur J Med Genet"},{"issue":"2","key":"3740_CR78","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2016.03.059","volume":"139","author":"HH Chen","year":"2017","unstructured":"Chen HH, H\u00e4ndel N, Ngeow J, Muller J, H\u00fchn M, Yang HT, et al. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: analysis of FOXP3 regulatory T cells. J Allergy Clin Immunol. 2017;139(2):607-20.e15.","journal-title":"J Allergy Clin Immunol"},{"issue":"20","key":"3740_CR79","doi-asserted-by":"publisher","first-page":"3393","DOI":"10.1093\/hmg\/ddac111","volume":"31","author":"S Srivastava","year":"2022","unstructured":"Srivastava S, Jo B, Zhang B, Frazier T, Gallagher AS, Peck F, et al. A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. Hum Mol Genet. 2022;31(20):3393\u2013404.","journal-title":"Hum Mol Genet"},{"issue":"12","key":"3740_CR80","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1634\/theoncologist.2019-0514","volume":"24","author":"T Komiya","year":"2019","unstructured":"Komiya T, Blumenthal GM, DeChowdhury R, Fioravanti S, Ballas MS, Morris J, et al. A pilot study of sirolimus in subjects with cowden syndrome or other syndromes characterized by germline mutations in PTEN. Oncologist. 2019;24(12):1510-e265.","journal-title":"Oncologist"},{"key":"3740_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29603","author":"KA Shimano","year":"2022","unstructured":"Shimano KA, Eng W, Adams DM. How we approach the use of sirolimus and new agents: medical therapy to treat vascular anomalies. Pediatr Blood Cancer. 2022. https:\/\/doi.org\/10.1002\/pbc.29603.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"3740_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00130","volume":"3","author":"B Kingston","year":"2019","unstructured":"Kingston B, Bailleux C, Delaloge S, Schiavon G, Scott V, Lacroix-Triki M, et al. Exceptional response to AKT inhibition in patients with breast cancer and germline PTEN mutations. JCO Precis Oncol. 2019;3(3):1\u20137.","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"3740_CR83","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/path.6009","volume":"258","author":"P Tibarewal","year":"2022","unstructured":"Tibarewal P, Rathbone V, Constantinou G, Pearce W, Adil M, Varyova Z, et al. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development. J Pathol. 2022;258(4):382\u201394.","journal-title":"J Pathol"},{"issue":"11","key":"3740_CR84","doi-asserted-by":"publisher","first-page":"e79639","DOI":"10.1371\/journal.pone.0079639","volume":"8","author":"A Tchekmedyian","year":"2013","unstructured":"Tchekmedyian A, Amos CI, Bale SJ, Zhu D, Arold S, Berrueta J, et al. Findings from the Peutz-Jeghers syndrome registry of uruguay. PLoS ONE. 2013;8(11):e79639.","journal-title":"PLoS ONE"},{"issue":"7","key":"3740_CR85","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1136\/gut.2009.198499","volume":"59","author":"AD Beggs","year":"2010","unstructured":"Beggs AD, Latchford AR, Vasen HFA, Moslein G, Alonso A, Aretz S, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut. 2010;59(7):975\u201386.","journal-title":"Gut"},{"issue":"6663","key":"3740_CR86","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/34432","volume":"391","author":"A Hemminki","year":"1998","unstructured":"Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, et al. A serine\/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature. 1998;391(6663):184\u20137.","journal-title":"Nature"},{"issue":"1","key":"3740_CR87","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/ng0198-38","volume":"18","author":"DE Jenne","year":"1998","unstructured":"Jenne DE, Reomann H, Nezu J, Friedel W, Loff S, Jeschke R, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threoninekinase. Nat Genet. 1998;18(1):38\u201343.","journal-title":"Nat Genet"},{"issue":"6","key":"3740_CR88","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1086\/302159","volume":"63","author":"H Mehenni","year":"1998","unstructured":"Mehenni H, Gehrig C, Nezu J, Oku A, Shimane M, Rossier C, et al. Loss of LKB1 kinase activity in peutz-jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Human Genet. 1998;63(6):1641\u201350.","journal-title":"Am J Human Genet"},{"issue":"1","key":"3740_CR89","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/jmg.35.1.42","volume":"35","author":"S Olschwang","year":"1998","unstructured":"Olschwang S, Markie D, Seal S, Neale K, Phillips R, Cottrell S, et al. Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3. J Med Genet. 1998;35(1):42\u20134.","journal-title":"J Med Genet"},{"issue":"4","key":"3740_CR90","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/sj.emboj.7600110","volume":"23","author":"JM Lizcano","year":"2004","unstructured":"Lizcano JM, G\u00f6ransson O, Toth R, Deak M, Morrice NA, Boudeau J, et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK\/PAR-1. Embo j. 2004;23(4):833\u201343.","journal-title":"Embo j"},{"issue":"6","key":"3740_CR91","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1097-2765(01)00258-1","volume":"7","author":"P Karuman","year":"2001","unstructured":"Karuman P, Gozani O, Odze RD, Zhou XC, Zhu H, Shaw R, et al. The Peutz-Jegher Gene Product LKB1 Is a Mediator of p53-Dependent Cell Death. Mol Cell. 2001;7(6):1307\u201319.","journal-title":"Mol Cell"},{"issue":"4","key":"3740_CR92","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1042\/BST20130030","volume":"41","author":"EA Dunlop","year":"2013","unstructured":"Dunlop EA, Tee AR. The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homoeostasis. Biochem Soc Trans. 2013;41(4):939\u201343.","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"3740_CR93","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.bpg.2009.02.007","volume":"23","author":"A Gammon","year":"2009","unstructured":"Gammon A, Jasperson K, Kohlmann W, Burt RW. Hamartomatous polyposis syndromes. Best Pract Res Clin Gastroenterol. 2009;23(2):219\u201331.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"12","key":"3740_CR94","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1097\/DCR.0b013e318233a11f","volume":"54","author":"AR Latchford","year":"2011","unstructured":"Latchford AR, Neale K, Phillips RKS, Clark SK. Peutz-Jeghers syndrome: intriguing suggestion of gastrointestinal cancer prevention from surveillance. Dis Colon Rectum. 2011;54(12):1547\u201351.","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"3740_CR95","first-page":"219","volume":"39","author":"R Hinds","year":"2004","unstructured":"Hinds R, Philp C, Hyer W, Fell JM. Complications of childhood peutz-jeghers syndrome: implications for pediatric screening. J Pediatr Gastroenterol Nutr. 2004;39(2):219\u201320.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"3740_CR96","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ajg.2010.473","volume":"106","author":"MGF van Lier","year":"2011","unstructured":"van Lier MGF, Mathus-Vliegen EMH, Wagner A, van Leerdam ME, Kuipers EJ. High cumulative risk of intussusception in patients with peutz-jeghers syndrome: time to update surveillance guidelines? Am J Gastroenterol. 2011;106(5):940\u20135.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"3740_CR97","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1158\/1078-0432.CCR-06-0083","volume":"12","author":"N Hearle","year":"2006","unstructured":"Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJP, et al. Frequency and spectrum of cancers in the peutz-jeghers syndrome. Clin Cancer Res. 2006;12(10):3209\u201315.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3740_CR98","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1136\/gut.2005.082990","volume":"55","author":"H Mehenni","year":"2006","unstructured":"Mehenni H, Resta N, Park J-G, Miyaki M, Guanti G, Costanza MC. Cancer risks in LKB1 germline mutation carriers. Gut. 2006;55(7):984\u201390.","journal-title":"Gut"},{"issue":"2","key":"3740_CR99","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gut.2010.223750","volume":"60","author":"MGF van Lier","year":"2011","unstructured":"van Lier MGF, Westerman AM, Wagner A, Looman CWN, Wilson JHP, de Rooij FWM, et al. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut. 2011;60(2):141\u20137.","journal-title":"Gut"},{"issue":"1","key":"3740_CR100","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/jmedgenet-2012-101277","volume":"50","author":"SE Korsse","year":"2012","unstructured":"Korsse SE, Harinck F, van Lier MGF, Biermann K, Offerhaus GJA, Krak N, et al. Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet. 2012;50(1):59\u201364.","journal-title":"J Med Genet"},{"issue":"7","key":"3740_CR101","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.dld.2012.12.018","volume":"45","author":"N Resta","year":"2013","unstructured":"Resta N, Pierannunzio D, Lenato GM, Stella A, Capocaccia R, Bagnulo R, et al. Cancer risk associated with STK11\/LKB1 germline mutations in Peutz-Jeghers syndrome patients: Results of an Italian multicenter study. Dig Liver Dis. 2013;45(7):606\u201311.","journal-title":"Dig Liver Dis"},{"issue":"11","key":"3740_CR102","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s00595-015-1296-y","volume":"46","author":"H Ishida","year":"2016","unstructured":"Ishida H, Tajima Y, Gonda T, Kumamoto K, Ishibashi K, Iwama T. Update on our investigation of malignant tumors associated with Peutz-Jeghers syndrome in Japan. Surg Today. 2016;46(11):1231\u201342.","journal-title":"Surg Today"},{"key":"3740_CR103","doi-asserted-by":"crossref","unstructured":"Chen H-Y, Jin X-W, Li B-R, Zhu M, Li J, Mao G-P, et al. Cancer risk in patients with Peutz\u2013Jeghers syndrome: A retrospective cohort study of 336 cases. Tumor Biol. 2017;39(6).","DOI":"10.1177\/1010428317705131"},{"key":"3740_CR104","doi-asserted-by":"crossref","unstructured":"Wagner A, Aretz S, Auranen A, Bruno MJ, Cavestro GM, Crosbie EJ, et al. The Management of Peutz\u2013Jeghers Syndrome: European Hereditary Tumour Group (EHTG) Guideline. Journal of Clinical Medicine. 2021;10(3).","DOI":"10.3390\/jcm10030473"},{"issue":"2","key":"3740_CR105","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.canlet.2008.11.036","volume":"277","author":"C Wei","year":"2009","unstructured":"Wei C, Amos CI, Zhang N, Zhu J, Wang X, Frazier ML. Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model. Cancer Lett. 2009;277(2):149\u201354.","journal-title":"Cancer Lett"},{"issue":"3","key":"3740_CR106","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10689-011-9471-9","volume":"10","author":"SK Kuwada","year":"2011","unstructured":"Kuwada SK, Burt R. A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome. Fam Cancer. 2011;10(3):469\u201372.","journal-title":"Fam Cancer"},{"issue":"111","key":"3740_CR107","doi-asserted-by":"publisher","first-page":"pe8","DOI":"10.1126\/scisignal.3111pe8","volume":"3","author":"T Rajakulendran","year":"2010","unstructured":"Rajakulendran T, Sicheri F. Allosteric protein kinase regulation by pseudokinases: insights from STRAD. Sci Signal. 2010;3(111):pe8.","journal-title":"Sci Signal"},{"issue":"8","key":"3740_CR108","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1002\/ajmg.a.37727","volume":"170","author":"W Bi","year":"2016","unstructured":"Bi W, Glass IA, Muzny DM, Gibbs RA, Eng CM, Yang Y, et al. Whole exome sequencing identifies the first STRADA point mutation in a patient with polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome (PMSE). Am J Med Genet A. 2016;170(8):2181\u20135.","journal-title":"Am J Med Genet A"},{"issue":"182","key":"3740_CR109","doi-asserted-by":"publisher","first-page":"182RA53","DOI":"10.1126\/scitranslmed.3005271","volume":"5","author":"WE Parker","year":"2013","unstructured":"Parker WE, Orlova KA, Parker WH, Birnbaum JF, Krymskaya VP, Goncharov DA, et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med. 2013;5(182):182RA53.","journal-title":"Sci Transl Med"},{"key":"3740_CR110","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fncel.2020.00122","volume":"14","author":"LT Dang","year":"2020","unstructured":"Dang LT, Glanowska KM, Iffland Ii PH, Barnes AE, Baybis M, Liu Y, et al. Multimodal Analysis of STRADA Function in Brain Development. Front Cell Neurosci. 2020;14:122.","journal-title":"Front Cell Neurosci"},{"issue":"5","key":"3740_CR111","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/dneu.22816","volume":"81","author":"LT Dang","year":"2021","unstructured":"Dang LT, Vaid S, Lin G, Swaminathan P, Safran J, Loughman A, et al. STRADA-mutant human cortical organoids model megalencephaly and exhibit delayed neuronal differentiation. Dev Neurobiol. 2021;81(5):696\u2013709.","journal-title":"Dev Neurobiol"},{"issue":"9114","key":"3740_CR112","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(05)78872-3","volume":"351","author":"FJ O'Callaghan","year":"1998","unstructured":"O\u2019Callaghan FJ, Shiell AW, Osborne JP, Martyn CN. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;351(9114):1490.","journal-title":"Lancet"},{"key":"3740_CR113","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.seizure.2021.06.027","volume":"91","author":"A Strzelczyk","year":"2021","unstructured":"Strzelczyk A, Rosenow F, Z\u00f6llner JP, Simon A, Wyatt G, Holland R, et al. Epidemiology, healthcare resource use, and mortality in patients with tuberous sclerosis complex: a population-based study on German health insurance data. Seizure. 2021;91:287\u201395.","journal-title":"Seizure"},{"issue":"1","key":"3740_CR114","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13023-020-01517-2","volume":"15","author":"WC Chu","year":"2020","unstructured":"Chu WC, Chiang LL, Chan DC, Wong WH, Chan GC. Prevalence, mortality and healthcare economic burden of tuberous sclerosis in Hong Kong: a population-based retrospective cohort study (1995\u20132018). Orphanet J Rare Dis. 2020;15(1):264.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3740_CR115","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13023-018-0870-y","volume":"13","author":"D Ebrahimi-Fakhari","year":"2018","unstructured":"Ebrahimi-Fakhari D, Mann LL, Poryo M, Graf N, von Kries R, Heinrich B, et al. Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis. 2018;13(1):117.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3740_CR116","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243\u201354.","journal-title":"Pediatr Neurol"},{"issue":"5327","key":"3740_CR117","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M van Slegtenhorst","year":"1997","unstructured":"van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805\u20138.","journal-title":"Science"},{"issue":"7","key":"3740_CR118","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","volume":"75","author":"Consortium ECTS","year":"1993","unstructured":"Consortium ECTS. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305\u201315.","journal-title":"Cell"},{"issue":"2","key":"3740_CR119","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","volume":"169","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR Signaling in growth, metabolism, and disease. Cell. 2017;169(2):361\u201371.","journal-title":"Cell"},{"key":"3740_CR120","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.pediatrneurol.2019.03.003","volume":"96","author":"LS Farach","year":"2019","unstructured":"Farach LS, Pearson DA, Woodhouse JP, Schraw JM, Sahin M, Krueger DA, et al. Tuberous sclerosis complex genotypes and developmental phenotype. Pediatr Neurol. 2019;96:58\u201363.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"3740_CR121","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1086\/316951","volume":"68","author":"SL Dabora","year":"2001","unstructured":"Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64\u201380.","journal-title":"Am J Hum Genet"},{"key":"3740_CR122","doi-asserted-by":"publisher","first-page":"101086","DOI":"10.1016\/j.spen.2023.101086","volume":"47","author":"P Curatolo","year":"2023","unstructured":"Curatolo P, Trivisano M, Specchio N. Updated genotype-phenotype correlations in TSC. Semin Pediatr Neurol. 2023;47:101086.","journal-title":"Semin Pediatr Neurol"},{"issue":"2","key":"3740_CR123","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/00000478-200202000-00006","volume":"26","author":"G Martignoni","year":"2002","unstructured":"Martignoni G, Bonetti F, Pea M, Tardanico R, Brunelli M, Eble JN. Renal disease in adults with TSC2\/PKD1 contiguous gene syndrome. Am J Surg Pathol. 2002;26(2):198\u2013205.","journal-title":"Am J Surg Pathol"},{"key":"3740_CR124","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1749-6632.2009.05117.x","volume":"1184","author":"KA Orlova","year":"2010","unstructured":"Orlova KA, Crino PB. The tuberous sclerosis complex. Ann N Y Acad Sci. 2010;1184:87\u2013105.","journal-title":"Ann N Y Acad Sci"},{"key":"3740_CR125","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pediatrneurol.2021.07.011","volume":"123","author":"H Northrup","year":"2021","unstructured":"Northrup H, Aronow ME, Bebin EM, Bissler J, Darling TN, de Vries PJ, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021;123:50\u201366.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"3740_CR126","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13023-016-0553-5","volume":"12","author":"JC Kingswood","year":"2017","unstructured":"Kingswood JC, d\u2019Aug\u00e8res GB, Belousova E, Ferreira JC, Carter T, Castellana R, et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. 2017;12(1):2.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3740_CR127","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9149(03)00677-5","volume":"92","author":"W Tworetzky","year":"2003","unstructured":"Tworetzky W, McElhinney DB, Margossian R, Moon-Grady AJ, Sallee D, Goldmuntz E, et al. Association between cardiac tumors and tuberous sclerosis in the fetus and neonate. Am J Cardiol. 2003;92(4):487\u20139.","journal-title":"Am J Cardiol"},{"issue":"6","key":"3740_CR128","doi-asserted-by":"publisher","first-page":"e001493","DOI":"10.1161\/JAHA.114.001493","volume":"3","author":"RB Hinton","year":"2014","unstructured":"Hinton RB, Prakash A, Romp RL, Krueger DA, Knilans TK. Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group. J Am Heart Assoc. 2014;3(6):e001493.","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"3740_CR129","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/0002-9149(90)91109-J","volume":"66","author":"JF Smythe","year":"1990","unstructured":"Smythe JF, Dyck JD, Smallhorn JF, Freedom RM. Natural history of cardiac rhabdomyoma in infancy and childhood. Am J Cardiol. 1990;66(17):1247\u20139.","journal-title":"Am J Cardiol"},{"issue":"12","key":"3740_CR130","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1046\/j.1365-4362.1998.00495.x","volume":"37","author":"S J\u00f3\u017awiak","year":"1998","unstructured":"J\u00f3\u017awiak S, Schwartz RA, Janniger CK, Micha\u0142owicz R, Chmielik J. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol. 1998;37(12):911\u20137.","journal-title":"Int J Dermatol"},{"key":"3740_CR131","doi-asserted-by":"crossref","unstructured":"Klonowska K, Grevelink JM, Giannikou K, Ogorek BA, Herbert ZT, Thorner AR, et al. Ultrasensitive profiling of UV-induced mutations identifies thousands of subclinical facial tumors in tuberous sclerosis complex. J Clin Invest. 2022;132(10).","DOI":"10.1172\/JCI155858"},{"issue":"5","key":"3740_CR132","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ejpn.2018.05.006","volume":"22","author":"P Curatolo","year":"2018","unstructured":"Curatolo P, Nabbout R, Lagae L, Aronica E, Ferreira JC, Feucht M, et al. Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol. 2018;22(5):738\u201348.","journal-title":"Eur J Paediatr Neurol"},{"issue":"7","key":"3740_CR133","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/brain\/awad048","volume":"146","author":"E Aronica","year":"2023","unstructured":"Aronica E, Specchio N, Luinenburg MJ, Curatolo P. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy. Brain. 2023;146(7):2694\u2013710.","journal-title":"Brain"},{"key":"3740_CR134","doi-asserted-by":"crossref","unstructured":"Roth J, Roach ES, Bartels U, J\u00f3\u017awiak S, Koenig MK, Weiner HL, et al. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol. 2013;49(6):439\u201344.","DOI":"10.1016\/j.pediatrneurol.2013.08.017"},{"issue":"3","key":"3740_CR135","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1515\/revneuro-2017-0027","volume":"29","author":"DL Chan","year":"2018","unstructured":"Chan DL, Calder T, Lawson JA, Mowat D, Kennedy SE. The natural history of subependymal giant cell astrocytomas in tuberous sclerosis complex: a review. Rev Neurosci. 2018;29(3):295\u2013301.","journal-title":"Rev Neurosci"},{"issue":"1","key":"3740_CR136","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13023-018-0901-8","volume":"13","author":"PJ de Vries","year":"2018","unstructured":"de Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis. 2018;13(1):157.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3740_CR137","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/dmcn.14356","volume":"62","author":"C Tye","year":"2020","unstructured":"Tye C, McEwen FS, Liang H, Underwood L, Woodhouse E, Barker ED, et al. Long-term cognitive outcomes in tuberous sclerosis complex. Dev Med Child Neurol. 2020;62(3):322\u20139.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"3740_CR138","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1111\/epi.17507","volume":"64","author":"C Tye","year":"2023","unstructured":"Tye C, McEwen FS, Liang H, Woodhouse E, Underwood L, Shephard E, et al. Epilepsy severity mediates association between mutation type and ADHD symptoms in tuberous sclerosis complex. Epilepsia. 2023;64(3):e30\u20135.","journal-title":"Epilepsia"},{"issue":"6","key":"3740_CR139","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1464-410X.2004.05046.x","volume":"94","author":"FJ O'Callaghan","year":"2004","unstructured":"O\u2019Callaghan FJ, Noakes MJ, Martyn CN, Osborne JP. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 2004;94(6):853\u20137.","journal-title":"BJU Int"},{"issue":"2","key":"3740_CR140","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/PAP.0000000000000419","volume":"31","author":"RB Shah","year":"2024","unstructured":"Shah RB, Mehra R. Renal cell carcinoma associated with TSC\/MTOR genomic alterations: an update on its expanding spectrum and an approach to clinicopathologic work-up. Adv Anat Pathol. 2024;31(2):105\u201317.","journal-title":"Adv Anat Pathol"},{"issue":"10","key":"3740_CR141","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3390\/genes12101585","volume":"12","author":"EP Henske","year":"2021","unstructured":"Henske EP, Cornejo KM, Wu CL. Renal cell carcinoma in tuberous sclerosis complex. Genes. 2021;12(10):895.","journal-title":"Genes"},{"issue":"4","key":"3740_CR142","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/ndt\/14.4.988","volume":"14","author":"A Clarke","year":"1999","unstructured":"Clarke A, Hancock E, Kingswood C, Osborne JP. End-stage renal failure in adults with the tuberous sclerosis complex. Nephrol Dial Transplant. 1999;14(4):988\u201391.","journal-title":"Nephrol Dial Transplant"},{"issue":"10433","key":"3740_CR143","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","volume":"403","author":"K Wong","year":"2024","unstructured":"Wong K, Pitcher D, Braddon F, Downward L, Steenkamp R, Annear N, et al. Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort. Lancet. 2024;403(10433):1279\u201389.","journal-title":"Lancet"},{"issue":"6","key":"3740_CR144","doi-asserted-by":"publisher","first-page":"e0158476","DOI":"10.1371\/journal.pone.0158476","volume":"11","author":"DN Franz","year":"2016","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost MD, Kuperman R, et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS ONE. 2016;11(6):e0158476.","journal-title":"PLoS ONE"},{"issue":"8","key":"3740_CR145","doi-asserted-by":"publisher","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","volume":"12","author":"JJ Bissler","year":"2017","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. PLoS ONE. 2017;12(8):e0180939.","journal-title":"PLoS ONE"},{"issue":"17","key":"3740_CR146","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595\u2013606.","journal-title":"N Engl J Med"},{"issue":"9","key":"3740_CR147","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.3390\/ijerph18094907","volume":"18","author":"M Sugalska","year":"2021","unstructured":"Sugalska M, Tomik A, J\u00f3\u017awiak S, Werner B. Treatment of cardiac rhabdomyomas with mtor inhibitors in children with tuberous sclerosis complex-a systematic review. Int J Environ Res Public Health. 2021;18(9):4907.","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"3740_CR148","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/jmedgenet-2013-101680","volume":"50","author":"JM Capo-Chichi","year":"2013","unstructured":"Capo-Chichi JM, Tcherkezian J, Hamdan FF, Decarie JC, Dobrzeniecka S, Patry L, et al. Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly. J Med Genet. 2013;50(11):740\u20134.","journal-title":"J Med Genet"},{"issue":"4","key":"3740_CR149","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/humu.22529","volume":"35","author":"AA Alfaiz","year":"2014","unstructured":"Alfaiz AA, Micale L, Mandriani B, Augello B, Pellico MT, Chrast J, et al. TBC1D7 mutations are associated with intellectual disability, macrocrania, patellar dislocation, and celiac disease. Hum Mutat. 2014;35(4):447\u201351.","journal-title":"Hum Mutat"},{"issue":"2","key":"3740_CR150","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ajhg.2022.12.015","volume":"110","author":"J Dekker","year":"2023","unstructured":"Dekker J, Schot R, Bongaerts M, de Valk WG, van Veghel-Plandsoen MM, Monfils K, et al. Web-accessible application for identifying pathogenic transcripts with RNA-seq: Increased sensitivity in diagnosis of neurodevelopmental disorders. Am J Hum Genet. 2023;110(2):251\u201372.","journal-title":"Am J Hum Genet"},{"issue":"7","key":"3740_CR151","doi-asserted-by":"publisher","first-page":"110824","DOI":"10.1016\/j.celrep.2022.110824","volume":"39","author":"S Schrotter","year":"2022","unstructured":"Schrotter S, Yuskaitis CJ, MacArthur MR, Mitchell SJ, Hosios AM, Osipovich M, et al. The non-essential TSC complex component TBC1D7 restricts tissue mTORC1 signaling and brain and neuron growth. Cell Rep. 2022;39(7):110824.","journal-title":"Cell Rep"},{"key":"3740_CR152","doi-asserted-by":"publisher","DOI":"10.1016\/S1874-6047(10)27003-8","author":"N Parmar","year":"2010","unstructured":"Parmar N, Tamanoi F. Rheb G-proteins and the activation of mTORC1- PubMed. Enzymes. 2010. https:\/\/doi.org\/10.1016\/S1874-6047(10)27003-8.","journal-title":"Enzymes"},{"issue":"1","key":"3740_CR153","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.devcel.2010.11.020","volume":"20","author":"J Zou","year":"2011","unstructured":"Zou J, Zhou L, Du X-X, Ji Y, Xu J, Tian J, et al. Rheb1 Is required for mTORC1 and myelination in postnatal brain development. Dev Cell. 2011;20(1):97\u2013108.","journal-title":"Dev Cell"},{"key":"3740_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00933-6","author":"MRF Reijnders","year":"2017","unstructured":"Reijnders MRF, Kousi M, van Woerden GM, Klein M, Bralten J, Mancini GMS, et al. Variation in a range of mTOR-related genes associates with intracranial volume and intellectual disability. Nat Commun. 2017. https:\/\/doi.org\/10.1038\/s41467-017-00933-6.","journal-title":"Nat Commun"},{"issue":"1","key":"3740_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14581\/jer.18001","volume":"8","author":"J-S Kim","year":"2018","unstructured":"Kim J-S, Park E-K, Shim K-W, Kim DS. Hemispherotomy and Functional Hemispherectomy: indications and Outcomes. J Epilepsy Res. 2018;8(1):1\u20135.","journal-title":"J Epilepsy Res"},{"issue":"2","key":"3740_CR156","first-page":"63","volume":"2","author":"LD Smith","year":"2013","unstructured":"Smith LD, Saunders CJ, Dinwiddie DL, Atherton AM, Miller NA, Soden SE, et al. Exome sequencing reveals de novo germline mutation of the mammalian target of rapamycin (MTOR) in a patient with megalencephaly and intractable seizures. J Genomes Exomes. 2013;2(2):63\u201372.","journal-title":"J Genomes Exomes"},{"issue":"3","key":"3740_CR157","doi-asserted-by":"publisher","first-page":"e432","DOI":"10.1212\/NXG.0000000000000432","volume":"6","author":"A Elizondo-Plazas","year":"2020","unstructured":"Elizondo-Plazas A, Ibarra-Ram\u00edrez M, Garza-B\u00e1ez A, Mart\u00ednez-de-Villarreal LE. Expanding the phenotype of MTOR-related disorders and the Smith-Kingsmore syndrome. Neurol Genet. 2020;6(3):e432.","journal-title":"Neurol Genet"},{"issue":"4","key":"3740_CR158","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/cge.13135","volume":"93","author":"G Gordo","year":"2018","unstructured":"Gordo G, Tenorio J, Arias P, Santos-Simarro F, Garc\u00eda-Mi\u00f1aur S, Moreno JC, et al. mTOR mutations in smith-kingsmore syndrome: four additional patients and a review. Clin Genet. 2018;93(4):762\u201375.","journal-title":"Clin Genet"},{"issue":"8","key":"3740_CR159","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/ajmg.a.62350","volume":"185","author":"RL Poole","year":"2021","unstructured":"Poole RL, Curry PDK, Marcinkute R, Brewer C, Coman D, Hobson E, et al. Delineating the Smith-Kingsmore syndrome phenotype: Investigation of 16 patients with the MTOR c.5395G > A p.(Glu1799Lys) missense variant. Am J Med Genet Part A. 2021;185(8):2445\u201354.","journal-title":"Am J Med Genet Part A"},{"issue":"7","key":"3740_CR160","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/ajmg.a.37070","volume":"167","author":"G Baynam","year":"2015","unstructured":"Baynam G, Overkov A, Davis M, Mina K, Schofield L, Allcock R, et al. A germline MTOR mutation in aboriginal australian siblings with intellectual disability, dysmorphism, macrocephaly, and small thoraces. Am J Med Genet A. 2015;167(7):1659\u201367.","journal-title":"Am J Med Genet A"},{"key":"3740_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-015-0240-8","author":"C Mroske","year":"2015","unstructured":"Mroske C, Rasmussen K, Shinde DN, Huether R, Powis Z, Lu H-M, et al. Germline activating MTOR mutation arising through gonadal mosaicism in two brothers with megalencephaly and neurodevelopmental abnormalities. BMC Med Genet. 2015. https:\/\/doi.org\/10.1186\/s12881-015-0240-8.","journal-title":"BMC Med Genet"},{"key":"3740_CR162","unstructured":"Sanger. COSMIC|Catalogue of Somatic Mutations in Cancer 2024 [Available from: https:\/\/cancer.sanger.ac.uk\/cosmic."},{"key":"3740_CR163","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000118","author":"RS M\u00f8ller","year":"2016","unstructured":"M\u00f8ller RS, Weckhuysen S, Chipaux M, Marsan E, Taly V, Bebin EM, et al. Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy. Neurol Genet. 2016. https:\/\/doi.org\/10.1212\/NXG.0000000000000118.","journal-title":"Neurol Genet"},{"key":"3740_CR164","doi-asserted-by":"publisher","first-page":"631168","DOI":"10.3389\/fmed.2021.631168","volume":"8","author":"ME Muller","year":"2021","unstructured":"Muller ME, Daccord C, Taff\u00e9 P, Lazor R. Prevalence of birt-hogg-dub\u00e9 syndrome determined through epidemiological data on spontaneous pneumothorax and bayes theorem. Front Med. 2021;8:631168.","journal-title":"Front Med"},{"issue":"9","key":"3740_CR165","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.gim.2022.05.006","volume":"24","author":"JM Savatt","year":"2022","unstructured":"Savatt JM, Shimelis H, Moreno-De-Luca A, Strande NT, Oetjens MT, Ledbetter DH, et al. Frequency of truncating FLCN variants and Birt-Hogg-Dub\u00e9-associated phenotypes in a health care system population. Genet Med. 2022;24(9):1857\u201366.","journal-title":"Genet Med"},{"key":"3740_CR166","doi-asserted-by":"crossref","unstructured":"Ramirez Reyes JMJ, Cuesta R, Pause A. Folliculin: a regulator of transcription through ampk and mtor signaling pathways. Front Cell Dev Biol. 2021;9.","DOI":"10.3389\/fcell.2021.667311"},{"issue":"10","key":"3740_CR167","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrurol.2015.206","volume":"12","author":"LS Schmidt","year":"2015","unstructured":"Schmidt LS, Linehan WM. Molecular genetics and clinical features of Birt\u2013Hogg\u2013Dub\u00e9 syndrome. Nat Rev Urol. 2015;12(10):558\u201369.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"3740_CR168","doi-asserted-by":"publisher","first-page":"e0212952","DOI":"10.1371\/journal.pone.0212952","volume":"14","author":"PC Johannesma","year":"2019","unstructured":"Johannesma PC, van de Beek I, van der Wel TJWT, Reinhard R, Rozendaal L, Starink TM, et al. Renal imaging in 199 Dutch patients with birt-hogg-dub\u00e9 syndrome: screening compliance and outcome. PLoS ONE. 2019;14(3):e0212952.","journal-title":"PLoS ONE"},{"key":"3740_CR169","unstructured":"Birt-Hogg-Dub\u00e9 Syndrome [Available from: https:\/\/rarediseases.org\/rare-diseases\/birt-hogg-dube-syndrome\/. Accessed on 7th Oct 2024"},{"issue":"2","key":"3740_CR170","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/jnci\/djm288","volume":"100","author":"M Baba","year":"2008","unstructured":"Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, et al. Kidney-targeted birt-hogg-dube gene inactivation in a mouse model: Erk1\/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. JNCI J Natl Cancer Inst. 2008;100(2):140\u201354.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"7826","key":"3740_CR171","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-020-2444-0","volume":"585","author":"G Napolitano","year":"2020","unstructured":"Napolitano G, Di Malta C, Esposito A, de Araujo MEG, Pece S, Bertalot G, et al. A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dub\u00e9 syndrome. Nature. 2020;585(7826):597\u2013602.","journal-title":"Nature"},{"key":"3740_CR172","doi-asserted-by":"crossref","unstructured":"Epi25 C. Ultra-Rare genetic variation in the epilepsies: a whole-exome sequencing study of 17,606 individuals. Am J Hum Genet. 2019;105(2):267\u201382.","DOI":"10.1016\/j.ajhg.2019.05.020"},{"key":"3740_CR173","doi-asserted-by":"crossref","unstructured":"Consortium EK. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurol. 2017;16(2):135\u201343.","DOI":"10.1016\/S1474-4422(16)30359-3"},{"issue":"2","key":"3740_CR174","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41436-018-0060-2","volume":"21","author":"S Baldassari","year":"2019","unstructured":"Baldassari S, Picard F, Verbeek NE, van Kempen M, Brilstra EH, Lesca G, et al. The landscape of epilepsy-related GATOR1 variants. Genet Med. 2019;21(2):398\u2013408.","journal-title":"Genet Med"},{"key":"3740_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pbr.2016.04.013","author":"S Baulac","year":"2016","unstructured":"Baulac S. mTOR signaling pathway genes in focal epilepsies - PubMed. Progr Brain Res. 2016. https:\/\/doi.org\/10.1016\/bs.pbr.2016.04.013.","journal-title":"Progr Brain Res"},{"issue":"8","key":"3740_CR176","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/hmg\/ddaa068","volume":"29","author":"LK Klofas","year":"2020","unstructured":"Klofas LK, Short BP, Zhou C, Carson RP. Prevention of premature death and seizures in a Depdc5 mouse epilepsy model through inhibition of mTORC1. Hum Mol Genet. 2020;29(8):1365\u201377.","journal-title":"Hum Mol Genet"},{"key":"3740_CR177","doi-asserted-by":"publisher","first-page":"106951","DOI":"10.1016\/j.eplepsyres.2022.106951","volume":"184","author":"PB Moloney","year":"2022","unstructured":"Moloney PB, Dugan P, Widdess-Walsh P, Devinsky O, Delanty N. Genomics in the presurgical epilepsy evaluation. Epilepsy Res. 2022;184:106951.","journal-title":"Epilepsy Res"},{"issue":"4","key":"3740_CR178","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1212\/NXG.0000000000000028","volume":"1","author":"FA Nascimento","year":"2015","unstructured":"Nascimento FA, Borlot F, Cossette P, Minassian BA, Andrade DM. Two definite cases of sudden unexpected death in epilepsy in a family with a DEPDC5 mutation. Neurol Genet. 2015;1(4):e28.","journal-title":"Neurol Genet"},{"issue":"4","key":"3740_CR179","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24596","volume":"79","author":"RD Bagnall","year":"2016","unstructured":"Bagnall RD, Crompton DE, Petrovski S, Lam L, Cutmore C, Garry SI, et al. Exome-based analysis of cardiac arrhythmia, respiratory control, and epilepsy genes in sudden unexpected death in epilepsy. Ann Neurol. 2016;79(4):522\u201334.","journal-title":"Ann Neurol"},{"issue":"1","key":"3740_CR180","doi-asserted-by":"publisher","first-page":"e012264","DOI":"10.1161\/JAHA.119.012264","volume":"9","author":"CAA Chahal","year":"2020","unstructured":"Chahal CAA, Salloum MN, Alahdab F, Gottwald JA, Tester DJ, Anwer LA, et al. Systematic review of the genetics of sudden unexpected death in epilepsy: potential overlap with sudden cardiac death and arrhythmia-related genes. J Am Heart Assoc. 2020;9(1):e012264.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"3740_CR181","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/epi.13391","volume":"57","author":"S Weckhuysen","year":"2016","unstructured":"Weckhuysen S, Marsan E, Lambrecq V, Marchal C, Morin-Brureau M, An-Gourfinkel I, et al. Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia. Epilepsia. 2016;57(6):994\u20131003.","journal-title":"Epilepsia"},{"key":"3740_CR182","doi-asserted-by":"publisher","first-page":"100459","DOI":"10.1016\/j.ebr.2021.100459","volume":"16","author":"S Abumurad","year":"2021","unstructured":"Abumurad S, Issa NP, Wu S, Rose S, Taylan Esengul Y, Nordli D, et al. Laser interstitial thermal therapy for NPRL3-related epilepsy with multiple seizure foci: a case report. Epilepsy Behav Rep. 2021;16:100459.","journal-title":"Epilepsy Behav Rep"},{"key":"3740_CR183","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.seizure.2019.10.007","volume":"73","author":"M Vawter-Lee","year":"2019","unstructured":"Vawter-Lee M, Franz DN, Fuller CE, Greiner HM. Clinical Letter: A case report of targeted therapy with sirolimus for NPRL3 epilepsy. Seizure. 2019;73:43\u20135.","journal-title":"Seizure"},{"issue":"1","key":"3740_CR184","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ajhg.2013.10.001","volume":"94","author":"EL Baple","year":"2014","unstructured":"Baple EL, Maroofian R, Chioza BA, Izadi M, Cross HE, Al-Turki S, et al. Mutations in KPTN cause macrocephaly, neurodevelopmental delay, and Seizures. Am J Human Genet. 2014;94(1):87\u201394.","journal-title":"Am J Human Genet"},{"issue":"8","key":"3740_CR185","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/ajmg.a.37105","volume":"167","author":"S Pajusalu","year":"2015","unstructured":"Pajusalu S, Reimand T, \u00d5unap K. Novel homozygous mutation in KPTN gene causing a familial intellectual disability-macrocephaly syndrome. Am J Med Genet A. 2015;167(8):1913\u20135.","journal-title":"Am J Med Genet A"},{"issue":"4","key":"3740_CR186","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/ajmg.a.61492","volume":"182","author":"PH Lucena","year":"2020","unstructured":"Lucena PH, Armani-Franceschi G, Bispo-Torres AC, Bandeira ID, Lucena MFG, Maldonado I, et al. KPTN gene homozygous variant-related syndrome in the northeast of Brazil: a case report. Am J Med Genet A. 2020;182(4):762\u20137.","journal-title":"Am J Med Genet A"},{"issue":"10","key":"3740_CR187","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/ajmg.a.61778","volume":"182","author":"M Pacio Miguez","year":"2020","unstructured":"Pacio Miguez M, Santos-Simarro F, Garc\u00eda-Mi\u00f1a\u00far S, Vel\u00e1zquez Fragua R, del Pozo \u00c1, Sol\u00eds M, et al. Pathogenic variants in KPTN, a rare cause of macrocephaly and intellectual disability. Am J Med Genet A. 2020;182(10):2222\u20135.","journal-title":"Am J Med Genet A"},{"issue":"3","key":"3740_CR188","doi-asserted-by":"publisher","first-page":"a003970","DOI":"10.1101\/mcs.a003970","volume":"6","author":"I Thiffault","year":"2020","unstructured":"Thiffault I, Atherton A, Heese BA, Abdelmoity AT, Pawar K, Farrow E, et al. Pathogenic variants in KPTN gene identified by clinical whole-genome sequencing. Mol Case Stud. 2020;6(3):a003970.","journal-title":"Mol Case Stud"},{"key":"3740_CR189","doi-asserted-by":"publisher","first-page":"1113811","DOI":"10.3389\/fneur.2022.1113811","volume":"13","author":"S Horn","year":"2023","unstructured":"Horn S, Danyel M, Erdmann N, Boschann F, Gunnarsson C, Biskup S, et al. Case report: KPTN gene-related syndrome associated with a spectrum of neurodevelopmental anomalies including severe epilepsy. Front Neurol. 2023;13:1113811.","journal-title":"Front Neurol"},{"issue":"11","key":"3740_CR190","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1093\/brain\/awad231","volume":"146","author":"MO Levitin","year":"2023","unstructured":"Levitin MO, Rawlins LE, Sanchez-Andrade G, Arshad OA, Collins SC, Sawiak SJ, et al. Models of KPTN-related disorder implicate mTOR signalling in cognitive and overgrowth phenotypes. Brain. 2023;146(11):4766\u201383.","journal-title":"Brain"},{"key":"3740_CR191","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-016-0363-6","author":"Y Negishi","year":"2017","unstructured":"Negishi Y, Miya F, Hattori A, Johmura Y, Nakagawa M, Ando N, et al. A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly. BMC Med Genet. 2017. https:\/\/doi.org\/10.1186\/s12881-016-0363-6.","journal-title":"BMC Med Genet"},{"issue":"3","key":"3740_CR192","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ajhg.2013.07.005","volume":"93","author":"L Basel-Vanagaite","year":"2013","unstructured":"Basel-Vanagaite L, Hershkovitz T, Heyman E, Raspall-Chaure M, Kakar N, Smirin-Yosef P, et al. Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum. Am J Human Genet. 2013;93(3):524\u20139.","journal-title":"Am J Human Genet"},{"issue":"5","key":"3740_CR193","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1601-183X.2009.00509.x","volume":"8","author":"WN Frankel","year":"2009","unstructured":"Frankel WN, Yang Y, Mahaffey CL, Beyer BJ, O\u2019Brien TP. Szt2, a novel gene for seizure threshold in mice. Genes Brain Behav. 2009;8(5):568\u201376.","journal-title":"Genes Brain Behav"},{"issue":"7645","key":"3740_CR194","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature21378","volume":"543","author":"M Peng","year":"2017","unstructured":"Peng M, Yin N, Li MO. SZT2 dictates GATOR control of mTORC1 signalling. Nature. 2017;543(7645):433\u20137.","journal-title":"Nature"},{"issue":"11","key":"3740_CR195","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1474-4422(21)00265-9","volume":"20","author":"I Bl\u00fcmcke","year":"2021","unstructured":"Bl\u00fcmcke I, Budday S, Poduri A, Lal D, Kobow K, Baulac S. Neocortical development and epilepsy: insights from focal cortical dysplasia and brain tumours. Lancet Neurol. 2021;20(11):943\u201355.","journal-title":"Lancet Neurol"},{"issue":"1","key":"3740_CR196","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1528-1167.2010.02777.x","volume":"52","author":"I Bl\u00fcmcke","year":"2011","unstructured":"Bl\u00fcmcke I, Thom M, Aronica E, Armstrong DD, Vinters HV, Palmini A, et al. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission1. Epilepsia. 2011;52(1):158\u201374.","journal-title":"Epilepsia"},{"issue":"8","key":"3740_CR197","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/epi.17301","volume":"63","author":"I Najm","year":"2022","unstructured":"Najm I, Lal D, Alonso Vanegas M, Cendes F, Lopes-Cendes I, Palmini A, et al. The ILAE consensus classification of focal cortical dysplasia: An update proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia. 2022;63(8):1899\u2013919.","journal-title":"Epilepsia"},{"issue":"4","key":"3740_CR198","doi-asserted-by":"publisher","first-page":"facb222","DOI":"10.1093\/braincomms\/fcab222","volume":"3","author":"PB Moloney","year":"2021","unstructured":"Moloney PB, Cavalleri GL, Delanty N. Epilepsy in the mTORopathies: opportunities for precision medicine. Brain Commun. 2021;3(4):facb222.","journal-title":"Brain Commun"},{"issue":"17","key":"3740_CR199","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1056\/NEJMoa1703784","volume":"377","author":"I Bl\u00fcmcke","year":"2017","unstructured":"Bl\u00fcmcke I, Spreafico R, Haaker G, Coras R, Kobow K, Bien CG, et al. Histopathological findings in brain tissue obtained during epilepsy surgery. N Engl J Med. 2017;377(17):1648\u201356.","journal-title":"N Engl J Med"},{"issue":"6","key":"3740_CR200","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1172\/JCI99384","volume":"128","author":"T Ribierre","year":"2018","unstructured":"Ribierre T, Deleuze C, Bacq A, Baldassari S, Marsan E, Chipaux M, et al. Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia\u2013associated epilepsy. J Clin Investig. 2018;128(6):2452\u20138.","journal-title":"J Clin Investig"},{"issue":"7","key":"3740_CR201","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/acn3.50815","volume":"6","author":"WS Lee","year":"2019","unstructured":"Lee WS, Stephenson SEM, Howell KB, Pope K, Gillies G, Wray A, et al. Second-hit DEPDC5 mutation is limited to dysmorphic neurons in cortical dysplasia type IIA. Ann Clin Transl Neurol. 2019;6(7):1338\u201344.","journal-title":"Ann Clin Transl Neurol"},{"key":"3740_CR202","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad174","author":"R Checri","year":"2023","unstructured":"Checri R, Chipaux M, Ferrand-Sorbets S, Raffo E, Bulteau C, Rosenberg SD, et al. Detection of brain somatic mutations in focal cortical dysplasia during epilepsy presurgical workup. Brain Commun. 2023. https:\/\/doi.org\/10.1093\/braincomms\/fcad174.","journal-title":"Brain Commun"},{"issue":"3","key":"3740_CR203","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1177\/0883073818813238","volume":"34","author":"Q Xu","year":"2018","unstructured":"Xu Q, Uliel-Sibony S, Dunham C, Sarnat H, Flores-Sarnat L, Brunga L, et al. mTOR inhibitors as a new therapeutic strategy in treatment resistant epilepsy in hemimegalencephaly: a case report. J Child Neurol. 2018;34(3):132\u20138.","journal-title":"J Child Neurol"},{"issue":"6","key":"3740_CR204","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.braindev.2023.02.005","volume":"45","author":"H Shiraishi","year":"2023","unstructured":"Shiraishi H, Teramoto T, Yokoshiki S, Tohyama J, Ueda Y, Egawa K, et al. Efficacy of sirolimus for epileptic seizures in childhood associated with focal cortical dysplasia type II. Brain Develop. 2023;45(6):343\u20137.","journal-title":"Brain Develop"},{"issue":"5","key":"3740_CR205","doi-asserted-by":"publisher","first-page":"e0268597","DOI":"10.1371\/journal.pone.0268597","volume":"17","author":"DF Leitner","year":"2022","unstructured":"Leitner DF, Kanshin E, Askenazi M, Siu Y, Friedman D, Devore S, et al. Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia. PLoS ONE. 2022;17(5):e0268597.","journal-title":"PLoS ONE"},{"issue":"2","key":"3740_CR206","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/acn3.51505","volume":"9","author":"M Kato","year":"2022","unstructured":"Kato M, Kada A, Shiraishi H, Tohyama J, Nakagawa E, Takahashi Y, et al. Sirolimus for epileptic seizures associated with focal cortical dysplasia type II. Ann Clin Transl Neurol. 2022;9(2):181\u201392.","journal-title":"Ann Clin Transl Neurol"},{"key":"3740_CR207","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1197549","author":"J Park","year":"2023","unstructured":"Park J, Kim SH, Hahn J, Kang HC, Lee SG, Kim HD, et al. Population pharmacokinetics of everolimus in patients with seizures associated with focal cortical dysplasia. Front Pharmacol. 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1197549.","journal-title":"Front Pharmacol"},{"issue":"10","key":"3740_CR208","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.molmed.2018.08.003","volume":"24","author":"RR Madsen","year":"2018","unstructured":"Madsen RR, Vanhaesebroeck B, Semple RK. Cancer-associated PIK3CA mutations in overgrowth disorders. Trends Mol Med. 2018;24(10):856\u201370.","journal-title":"Trends Mol Med"},{"issue":"8","key":"3740_CR209","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/ng.2332","volume":"44","author":"MJ Lindhurst","year":"2012","unstructured":"Lindhurst MJ, Parker VER, Payne F, Sapp JC, Rudge S, Harris J, et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet. 2012;44(8):928\u201333.","journal-title":"Nat Genet"},{"issue":"2","key":"3740_CR210","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ajmg.a.36836","volume":"167","author":"KM Keppler-Noreuil","year":"2014","unstructured":"Keppler-Noreuil KM, Rios JJ, Parker VER, Semple RK, Lindhurst MJ, Sapp JC, et al. PIK3CA-related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 2014;167(2):287\u201395.","journal-title":"Am J Med Genet A"},{"issue":"11","key":"3740_CR211","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41431-023-01414-9","volume":"31","author":"G Reynolds","year":"2023","unstructured":"Reynolds G, Cardaropoli S, Carli D, Luca M, Gazzin A, Coppo P, et al. Epidemiology of the disorders of the Pik3ca-related overgrowth spectrum (Pros). Eur J Hum Genet. 2023;31(11):1333\u20136.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"3740_CR212","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/cge.14027","volume":"101","author":"S Douzgou","year":"2021","unstructured":"Douzgou S, Rawson M, Baselga E, Danielpour M, Faivre L, Kashanian A, et al. A standard of care for individuals with PIK3CA-related disorders: an international expert consensus statement. Clin Genet. 2021;101(1):32\u201347.","journal-title":"Clin Genet"},{"issue":"5","key":"3740_CR213","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41436-018-0297-9","volume":"21","author":"VER Parker","year":"2019","unstructured":"Parker VER, Keppler-Noreuil KM, Faivre L, Luu M, Oden NL, De Silva L, et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genet Med. 2019;21(5):1189\u201398.","journal-title":"Genet Med"},{"issue":"12","key":"3740_CR214","doi-asserted-by":"publisher","first-page":"100969","DOI":"10.1016\/j.gim.2023.100969","volume":"25","author":"G Canaud","year":"2023","unstructured":"Canaud G, Lopez Gutierrez JC, Irvine AD, Vabres P, Hansford JR, Ankrah N, et al. Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS). Genet Med. 2023;25(12):100969.","journal-title":"Genet Med"},{"issue":"1","key":"3740_CR215","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1158\/1078-0432.CCR-23-1270","volume":"30","author":"S Singh","year":"2024","unstructured":"Singh S, Bradford D, Li X, Mishra-Kalyani PS, Shen Y-L, Wang L, et al. FDA approval summary: alpelisib for PIK3CA-related overgrowth spectrum. Clin Cancer Res. 2024;30(1):23\u20138.","journal-title":"Clin Cancer Res"},{"key":"3740_CR216","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00228-9","author":"C McCarthy","year":"2021","unstructured":"McCarthy C, Gupta N, Johnson SR, Yu JJ, McCormack FX. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med. 2021. https:\/\/doi.org\/10.1016\/S2213-2600(21)00228-9.","journal-title":"Lancet Respir Med"},{"key":"3740_CR217","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1164\/ajrccm.164.4.2101154","volume":"164","author":"J Moss","year":"2001","unstructured":"Moss J, Avila NA, Barnes PM, Litzenberger RA, Bechtle J, Brooks PG, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med. 2001;164:669.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3740_CR218","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1164\/rccm.202310-1736LE","volume":"209","author":"E Lynn","year":"2023","unstructured":"Lynn E, Forde SH, Franciosi AN, Bendstrup E, Veltkamp M, Wind AE, et al. Updated prevalence of lymphangioleiomyomatosis in Europe. Am J Respir Crit Care Med. 2023;209(4):456\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"3740_CR219","first-page":"971","volume":"104","author":"EC Harknett","year":"2011","unstructured":"Harknett EC, Chang WYC, Byrnes S, Johnson J, Lazor R, Cohen MM, et al. Regional and national variability suggests underestimation of prevalence of lymphangioleiomyomatosis. Quarter J Med. 2011;104(11):971\u20139.","journal-title":"Quarter J Med"},{"issue":"3\u20134","key":"3740_CR220","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00439-006-0308-9","volume":"121","author":"P Kozlowski","year":"2007","unstructured":"Kozlowski P, Roberts P, Dabora S, Franz D, Bissler J, Northrup H, et al. Identification of 54 large deletions\/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet. 2007;121(3\u20134):389\u2013400.","journal-title":"Hum Genet"},{"issue":"5","key":"3740_CR221","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1513\/AnnalsATS.202008-911OC","volume":"18","author":"X Tian","year":"2021","unstructured":"Tian X, Glass JE, Kwiatkowski DJ, Towbin AJ, Li Y, Sund KL, et al. Lymphangioleiomyomatosis association with underlying genotype in patients with tuberous sclerosis complex. Ann Am Thorac Soc. 2021;18(5):815\u20139.","journal-title":"Ann Am Thorac Soc"},{"key":"3740_CR222","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jmg.2008.065342","volume":"46","author":"DA Muzykewicz","year":"2009","unstructured":"Muzykewicz DA, Sharma A, Muse V, Numis AL, Rajagopal J, Thiele EA. TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex. J Med Genet. 2009;46:465.","journal-title":"J Med Genet"},{"issue":"34","key":"3740_CR223","doi-asserted-by":"publisher","first-page":"30958","DOI":"10.1074\/jbc.M202678200","volume":"277","author":"EA Goncharova","year":"2002","unstructured":"Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 2002;277(34):30958\u201367.","journal-title":"J Biol Chem"},{"issue":"1","key":"3740_CR224","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1165\/rcmb.2014-0379RC","volume":"53","author":"C Priolo","year":"2015","unstructured":"Priolo C, Ricoult SJ, Khabibullin D, Filippakis H, Yu J, Manning BD, et al. Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol. 2015;53(1):33\u201341.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3740_CR225","doi-asserted-by":"publisher","first-page":"e0126025","DOI":"10.1371\/journal.pone.0126025","volume":"10","author":"D Clements","year":"2015","unstructured":"Clements D, Dongre A, Krymskyaya V, Johnson S. Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis. PLoS ONE. 2015;10:e0126025.","journal-title":"PLoS ONE"},{"key":"3740_CR226","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.202007-2854OC","volume":"4","author":"R Babaei-Jadidi","year":"2021","unstructured":"Babaei-Jadidi R, Dongre A, Miller S, Castellanos Uribe M, Stewart ID, Thompson ZM, et al. Mast cell tryptase release contributes to disease progression in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2021;4:431.","journal-title":"Am J Respir Crit Care Med"},{"key":"3740_CR227","doi-asserted-by":"crossref","unstructured":"Maisel K, Merrilees MJ, Atochina-Vasserman EN, Lian L, Obraztsova K, Rue R, et al. Immune Checkpoint Ligand PD-L1 is Upregulated in Pulmonary Lymphangioleiomyomatosis (LAM). American Journal of Respiratory Cell and Molecular Biology. 2018.","DOI":"10.1165\/rcmb.2018-0123OC"},{"issue":"8","key":"3740_CR228","doi-asserted-by":"publisher","first-page":"e98674","DOI":"10.1172\/jci.insight.98674","volume":"3","author":"H-J Liu","year":"2018","unstructured":"Liu H-J, Lizotte PH, Du H, Speranza MC, Lam HC, Vaughan S, et al. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti\u2013PD-1\/anti\u2013CTLA-4 immunotherapy. JCI Insight. 2018;3(8):e98674.","journal-title":"JCI Insight"},{"issue":"8","key":"3740_CR229","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1097\/01.pas.0000126859.70814.6d","volume":"28","author":"T Kumasaka","year":"2004","unstructured":"Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, Kondo T, et al. Lymphangiogenesis in Lymphangioleiomyomatosis: Its Implication in the Progression of Lymphangioleiomyomatosis. Am J Surg Pathol. 2004;28(8):1007\u201316.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"3740_CR230","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.ajpath.2017.04.014","volume":"187","author":"A Dongre","year":"2017","unstructured":"Dongre A, Clements D, Fisher AJ, Johnson SR. Cathepsin K in lymphangioleiomyomatosis: LAM cell-fibroblast interactions enhance protease activity by extracellular acidification. Am J Pathol. 2017;187(8):1750\u201362.","journal-title":"Am J Pathol"},{"key":"3740_CR231","unstructured":"Zhe X, Yang Y, Schuger L. Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor. Am J Respir Cell Mol Biol. 2004:2004\u20130289OC."},{"issue":"9","key":"3740_CR232","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0046-8177(97)90061-7","volume":"28","author":"T Hayashi","year":"1997","unstructured":"Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol. 1997;28(9):1071\u20138.","journal-title":"Hum Pathol"},{"issue":"2","key":"3740_CR233","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1164\/ajrccm.160.2.9901027","volume":"160","author":"SR Johnson","year":"1999","unstructured":"Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med. 1999;160(2):628\u201333.","journal-title":"Am J Respir Crit Care Med"},{"key":"3740_CR234","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","volume":"364","author":"FX McCormack","year":"2011","unstructured":"McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595\u2013606.","journal-title":"N Engl J Med"},{"issue":"12","key":"3740_CR235","doi-asserted-by":"publisher","first-page":"797","DOI":"10.7326\/0003-4819-154-12-201106210-00007","volume":"154","author":"AM Taveira-DaSilva","year":"2011","unstructured":"Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med. 2011;154(12):797\u2013805.","journal-title":"Ann Intern Med"},{"issue":"1","key":"3740_CR236","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1136\/thoraxjnl-2021-217809","volume":"78","author":"J Johnson","year":"2023","unstructured":"Johnson J, Stewart I, Johnson SR. Disease monitoring using lung function trajectory in lymphangioleiomyomatosis: assessment in two national cohorts. Thorax. 2023;78(1):61.","journal-title":"Thorax"},{"key":"3740_CR237","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/cjp2.162","volume":"6","author":"S Miller","year":"2020","unstructured":"Miller S, Stewart ID, Clements D, Soomro I, Babaei-Jadidi R, Johnson SR. Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response. J Pathol Clin Res. 2020;6:215.","journal-title":"J Pathol Clin Res"},{"issue":"7","key":"3740_CR238","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1104017","volume":"365","author":"MJ Lindhurst","year":"2011","unstructured":"Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, Peters K, et al. A mosaic activating mutation inAKT1Associated with the proteus syndrome. N Engl J Med. 2011;365(7):611\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"3740_CR239","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/sj.ejhg.5201638","volume":"14","author":"L Biesecker","year":"2006","unstructured":"Biesecker L. The challenges of Proteus syndrome: diagnosis and management. Eur J Hum Genet. 2006;14(11):1151\u20137.","journal-title":"Eur J Hum Genet"},{"issue":"12","key":"3740_CR240","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/gim.2017.65","volume":"19","author":"JC Sapp","year":"2017","unstructured":"Sapp JC, Hu L, Zhao J, Gruber A, Schwartz B, Ferrari D, et al. Quantifying survival in patients with Proteus syndrome. Genet Med. 2017;19(12):1376\u20139.","journal-title":"Genet Med"},{"key":"3740_CR241","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a004549","author":"LG Biesecker","year":"2020","unstructured":"Biesecker LG, Edwards M, O\u2019Donnell S, Doherty P, MacDougall T, Tith K, et al. Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092). Cold Spring Harbor Mol Case Stud. 2020. https:\/\/doi.org\/10.1101\/mcs.a004549.","journal-title":"Cold Spring Harbor Mol Case Stud"},{"issue":"2","key":"3740_CR242","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/cge.12266","volume":"85","author":"MM Cohen","year":"2013","unstructured":"Cohen MM. Proteus syndrome review: molecular, clinical, and pathologic features. Clin Genet. 2013;85(2):111\u20139.","journal-title":"Clin Genet"},{"issue":"1","key":"3740_CR243","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/jpn.JPN_139_16","volume":"12","author":"P Sachdeva","year":"2017","unstructured":"Sachdeva P, Minocha P, Jain R, Sitaraman S, Goyal M. Proteus syndrome with neurological manifestations: a rare presentation. J Pediatr Neurosci. 2017;12(1):109.","journal-title":"J Pediatr Neurosci"},{"key":"3740_CR244","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-CT035","author":"D Hyman","year":"2018","unstructured":"Hyman D, Bonafede M, O\u2019Cearbhaill R, Grisham R, Zamarin D, Tew W, et al. Abstract CT035: A phase Ib study of miransertib (ARQ 092) in combination with anastrozole in patients with PIK3CA or AKT1-mutant ER+ endometrial or ovarian cancer. Cancer Res. 2018. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-CT035.","journal-title":"Cancer Res"},{"issue":"7","key":"3740_CR245","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/ajmg.a.61160","volume":"179","author":"C Leoni","year":"2019","unstructured":"Leoni C, Gullo G, Resta N, Fagotti A, Onesimo R, Schwartz B, et al. First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma. Am J Med Genet A. 2019;179(7):1319\u201324.","journal-title":"Am J Med Genet A"},{"issue":"3","key":"3740_CR246","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ajhg.2019.01.015","volume":"104","author":"KM Keppler-Noreuil","year":"2019","unstructured":"Keppler-Noreuil KM, Sapp JC, Lindhurst MJ, Darling TN, Burton-Akright J, Bagheri M, et al. Pharmacodynamic study of miransertib in individuals with proteus syndrome. Am J Human Genet. 2019;104(3):484\u201391.","journal-title":"Am J Human Genet"},{"issue":"9861","key":"3740_CR247","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. The Lancet. 2013;381(9861):125\u201332.","journal-title":"The Lancet"},{"issue":"9869","key":"3740_CR248","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 2013;381(9869):817\u201324.","journal-title":"The Lancet"},{"issue":"10056","key":"3740_CR249","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. The Lancet. 2016;388(10056):2153\u201363.","journal-title":"The Lancet"},{"issue":"3","key":"3740_CR250","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/ana.20784","volume":"59","author":"DN Franz","year":"2006","unstructured":"Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59(3):490\u20138.","journal-title":"Ann Neurol"},{"issue":"6","key":"3740_CR251","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1164\/rccm.201607-1384ST","volume":"194","author":"FX McCormack","year":"2016","unstructured":"McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, et al. Official American thoracic society\/japanese respiratory society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med. 2016;194(6):748\u201361.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3740_CR252","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jamadermatol.2018.1408","volume":"154","author":"M Wataya-Kaneda","year":"2018","unstructured":"Wataya-Kaneda M, Ohno Y, Fujita Y, Yokozeki H, Niizeki H, Ogai M, et al. Sirolimus gel treatment vs placebo for facial angiofibromas in patients with tuberous sclerosis complex. JAMA Dermatol. 2018;154(7):781.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"3740_CR253","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","volume":"10","author":"J Rodon","year":"2013","unstructured":"Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143\u201353.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7711","key":"3740_CR254","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","volume":"558","author":"Q Venot","year":"2018","unstructured":"Venot Q, Blanc T, Rabia SH, Berteloot L, Ladraa S, Duong J-P, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature. 2018;558(7711):540\u20136.","journal-title":"Nature"},{"issue":"10","key":"3740_CR255","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","volume":"20","author":"B Vanhaesebroeck","year":"2021","unstructured":"Vanhaesebroeck B, Perry MWD, Brown JR, Andr\u00e9 F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021;20(10):741\u201369.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3740_CR256","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.molmed.2022.02.009","volume":"28","author":"RR Madsen","year":"2022","unstructured":"Madsen RR, Semple RK. PIK3CA-related overgrowth: silver bullets from the cancer arsenal? Trends Mol Med. 2022;28(4):255\u20137.","journal-title":"Trends Mol Med"},{"key":"3740_CR257","unstructured":"Agency EM. Withdrawal of application for the marketing authorisation of Vijoice (alpelisib): European Medicines Agency; 2023 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-application-marketing-authorisation-vijoice-alpelisib_en.pdf."},{"key":"3740_CR258","unstructured":"Administration FaD. FDA approves alpelisib for PIK3CA-related overgrowth spectrum: Food and Drug Administration; 2022 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-alpelisib-pik3ca-related-overgrowth-spectrum."},{"issue":"10","key":"3740_CR259","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","volume":"56","author":"SE Coutr\u00e9","year":"2015","unstructured":"Coutr\u00e9 SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10):2779\u201386.","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"3740_CR260","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","volume":"130","author":"VK Rao","year":"2017","unstructured":"Rao VK, Webster S, Dalm V, \u0160ediv\u00e1 A, van Hagen PM, Holland S, et al. Effective \u201cactivated PI3K\u03b4 syndrome\u201d-targeted therapy with the PI3K\u03b4 inhibitor leniolisib. Blood. 2017;130(21):2307\u201316.","journal-title":"Blood"},{"issue":"1","key":"3740_CR261","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaci.2023.09.032","volume":"153","author":"VK Rao","year":"2024","unstructured":"Rao VK, Kulm E, \u0160ediv\u00e1 A, Plebani A, Schuetz C, Shcherbina A, et al. Interim analysis: open-label extension study of leniolisib for patients with APDS. J Allergy Clin Immunol. 2024;153(1):265-74.e9.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3740_CR262","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","volume":"22","author":"ES Ali","year":"2022","unstructured":"Ali ES, Mitra K, Akter S, Ramproshad S, Mondal B, Khan IN, et al. Recent advances and limitations of mTOR inhibitors in the treatment of cancer. Cancer Cell Int. 2022;22(1):284.","journal-title":"Cancer Cell Int"},{"issue":"7606","key":"3740_CR263","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nature17963","volume":"534","author":"VS Rodrik-Outmezguine","year":"2016","unstructured":"Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, et al. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016;534(7606):272\u20136.","journal-title":"Nature"},{"issue":"7928","key":"3740_CR264","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41586-022-05213-y","volume":"609","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Fan Q, Luo X, Lou K, Weiss WA, Shokat KM. Brain-restricted mTOR inhibition with binary pharmacology. Nature. 2022;609(7928):822\u20138.","journal-title":"Nature"},{"issue":"1","key":"3740_CR265","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BST0390001","volume":"39","author":"DG Hardie","year":"2011","unstructured":"Hardie DG. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem Soc Trans. 2011;39(1):1\u201313.","journal-title":"Biochem Soc Trans"},{"key":"3740_CR266","doi-asserted-by":"publisher","first-page":"100715","DOI":"10.1016\/j.eclinm.2020.100715","volume":"32","author":"S Amin","year":"2021","unstructured":"Amin S, Mallick AA, Edwards H, Cortina-Borja M, Laugharne M, Likeman M, et al. The metformin in tuberous sclerosis (MiTS) study: a randomised double-blind placebo-controlled trial. EClinicalMedicine. 2021;32:100715.","journal-title":"EClinicalMedicine"},{"key":"3740_CR267","unstructured":"Medicines repurposing programme: annual highlights [Available from: https:\/\/www.england.nhs.uk\/long-read\/medicines-repurposing-programme-annual-highlights\/#building-a-repurposing-pipeline. Accessed on 7 Oct 2024"},{"issue":"10","key":"3740_CR268","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1111\/ene.15975","volume":"30","author":"PB Moloney","year":"2023","unstructured":"Moloney PB, Kearney H, Benson KA, Costello DJ, Cavalleri GL, Gorman KM, et al. Everolimus precision therapy for the GATOR1-related epilepsies: a case series. Eur J Neurol. 2023;30(10):3341\u20136.","journal-title":"Eur J Neurol"},{"issue":"6035","key":"3740_CR269","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1126\/science.1199498","volume":"332","author":"PP Hsu","year":"2011","unstructured":"Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011;332(6035):1317\u201322.","journal-title":"Science"},{"issue":"6035","key":"3740_CR270","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1126\/science.1199484","volume":"332","author":"Y Yu","year":"2011","unstructured":"Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011;332(6035):1322\u20136.","journal-title":"Science"},{"issue":"6125","key":"3740_CR271","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.1228771","volume":"339","author":"AM Robitaille","year":"2013","unstructured":"Robitaille AM, Christen S, Shimobayashi M, Cornu M, Fava LL, Moes S, et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science. 2013;339(6125):1320\u20133.","journal-title":"Science"},{"key":"3740_CR272","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.cell.2022.04.013","volume":"185","author":"S Battaglioni","year":"2022","unstructured":"Battaglioni S, Benjamin D, W\u00e4lchli M, Maier T, Hall MN. mTOR substrate phosphorylation in growth control. Cell. 2022;185:1814.","journal-title":"Cell"},{"issue":"19","key":"3740_CR273","doi-asserted-by":"publisher","first-page":"11175","DOI":"10.3390\/ijms231911175","volume":"23","author":"S Togi","year":"2022","unstructured":"Togi S, Ura H, Hatanaka H, Niida Y. Genotype and phenotype landscape of 283 Japanese patients with tuberous sclerosis complex. Int J Mol Sci. 2022;23(19):11175.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3740_CR274","doi-asserted-by":"publisher","first-page":"e1008007","DOI":"10.1371\/journal.pgen.1008007","volume":"15","author":"J Gong","year":"2019","unstructured":"Gong J, Wang F, Xiao B, Panjwani N, Lin F, Keenan K, et al. Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci. PLoS Genet. 2019;15(2):e1008007.","journal-title":"PLoS Genet"},{"issue":"6","key":"3740_CR275","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/ng.838","volume":"43","author":"FA Wright","year":"2011","unstructured":"Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet. 2011;43(6):539\u201346.","journal-title":"Nat Genet"},{"issue":"1","key":"3740_CR276","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41525-022-00299-9","volume":"7","author":"J Gong","year":"2022","unstructured":"Gong J, He G, Wang C, Bartlett C, Panjwani N, Mastromatteo S, et al. Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease. NPJ Genom Med. 2022;7(1):28.","journal-title":"NPJ Genom Med"},{"key":"3740_CR277","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1146\/annurev-genom-083117-021329","volume":"19","author":"WK O'Neal","year":"2018","unstructured":"O\u2019Neal WK, Knowles MR. Cystic fibrosis disease modifiers: complex genetics defines the phenotypic diversity in a monogenic disease. Annu Rev Genomics Hum Genet. 2018;19:201\u201322.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"4","key":"3740_CR278","doi-asserted-by":"publisher","first-page":"a022442","DOI":"10.1101\/cshperspect.a022442","volume":"5","author":"PB Crino","year":"2015","unstructured":"Crino PB. mTOR signaling in epilepsy: insights from malformations of cortical development. Cold Spring Harb Perspect Med. 2015;5(4):a022442.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3740_CR279","doi-asserted-by":"publisher","first-page":"664695","DOI":"10.3389\/fnana.2021.664695","volume":"15","author":"LH Nguyen","year":"2021","unstructured":"Nguyen LH, Bordey A. Convergent and divergent mechanisms of epileptogenesis in mTORopathies. Front Neuroanat. 2021;15:664695.","journal-title":"Front Neuroanat"},{"key":"3740_CR280","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.semcdb.2016.01.040","volume":"52","author":"AR Tee","year":"2016","unstructured":"Tee AR, Sampson JR, Pal DK, Bateman JM. The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex. Semin Cell Dev Biol. 2016;52:12\u201320.","journal-title":"Semin Cell Dev Biol"},{"key":"3740_CR281","doi-asserted-by":"publisher","first-page":"RP91010","DOI":"10.7554\/eLife.91010","volume":"12","author":"LH Nguyen","year":"2024","unstructured":"Nguyen LH, Xu Y, Nair M, Bordey A. The mTOR pathway genes MTOR, Rheb, Depdc5, Pten, and Tsc1 have convergent and divergent impacts on cortical neuron development and function. Elife. 2024;12:RP91010.","journal-title":"Elife"},{"issue":"4","key":"3740_CR282","doi-asserted-by":"publisher","first-page":"273","DOI":"10.7861\/clinmedicine.19-4-273","volume":"19","author":"J Barwell","year":"2019","unstructured":"Barwell J, Snape K, Wedderburn S. The new genomic medicine service and implications for patients. Clin Med. 2019;19(4):273\u20137.","journal-title":"Clin Med"},{"issue":"6","key":"3740_CR283","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ajhg.2023.04.002","volume":"110","author":"K Klonowska","year":"2023","unstructured":"Klonowska K, Giannikou K, Grevelink JM, Boeszoermenyi B, Thorner AR, Herbert ZT, et al. Comprehensive genetic and phenotype analysis of 95 individuals with mosaic tuberous sclerosis complex. Am J Hum Genet. 2023;110(6):979\u201388.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"3740_CR284","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41431-021-01022-5","volume":"30","author":"S Best","year":"2022","unstructured":"Best S, Vidic N, An K, Collins F, White SM. A systematic review of geographical inequities for accessing clinical genomic and genetic services for non-cancer related rare disease. Eur J Hum Genet. 2022;30(6):645\u201352.","journal-title":"Eur J Hum Genet"},{"key":"3740_CR285","unstructured":"Code on Genetic Testing and Insurance: the government's annual report 2023 [Available from: https:\/\/www.gov.uk\/government\/publications\/code-on-genetic-testing-and-insurance-annual-report-2023\/code-on-genetic-testing-and-insurance-the-governments-annual-report-2023. Accessed on 30th Sept 2024"},{"issue":"3","key":"3740_CR286","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1089\/lrb.2006.4.143","volume":"4","author":"K Seyama","year":"2006","unstructured":"Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol. 2006;4(3):143\u201352.","journal-title":"Lymphat Res Biol"},{"issue":"2","key":"3740_CR287","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1056\/NEJMc0707517","volume":"358","author":"LR Young","year":"2008","unstructured":"Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):199\u2013200.","journal-title":"N Engl J Med"},{"issue":"6","key":"3740_CR288","doi-asserted-by":"publisher","first-page":"e12336","DOI":"10.1002\/jev2.12336","volume":"12","author":"MN Bhaoighill","year":"2023","unstructured":"Bhaoighill MN, Falc\u00f3n-P\u00e9rez JM, Royo F, Tee AR, Webber JP, Dunlop EA. Tuberous Sclerosis Complex cell-derived EVs have an altered protein cargo capable of regulating their microenvironment and have potential as disease biomarkers. J Extracell Vesicles. 2023;12(6):e12336.","journal-title":"J Extracell Vesicles"},{"issue":"7","key":"3740_CR289","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.clinph.2018.03.010","volume":"129","author":"D Bernardo","year":"2018","unstructured":"Bernardo D, Nariai H, Hussain SA, Sankar R, Salamon N, Krueger DA, et al. Visual and semi-automatic non-invasive detection of interictal fast ripples: a potential biomarker of epilepsy in children with tuberous sclerosis complex. Clin Neurophysiol. 2018;129(7):1458\u201366.","journal-title":"Clin Neurophysiol"},{"issue":"8","key":"3740_CR290","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3390\/biomedicines10081838","volume":"10","author":"M Scheper","year":"2022","unstructured":"Scheper M, Romagnolo A, Besharat ZM, Iyer AM, Moavero R, Hertzberg C, et al. miRNAs and isomiRs: serum-based biomarkers for the development of intellectual disability and autism spectrum disorder in tuberous sclerosis complex. Biomedicines. 2022;10(8):1838.","journal-title":"Biomedicines"},{"issue":"Pt 8","key":"3740_CR291","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/brain\/awf175","volume":"125","author":"L Tassi","year":"2002","unstructured":"Tassi L, Colombo N, Garbelli R, Francione S, Lo Russo G, Mai R, et al. Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome. Brain. 2002;125(Pt 8):1719\u201332.","journal-title":"Brain"},{"key":"3740_CR292","doi-asserted-by":"publisher","first-page":"127418","DOI":"10.1016\/j.neucom.2024.127418","volume":"580","author":"Z Ganji","year":"2024","unstructured":"Ganji Z, Azizi S, Faraji R, Zare H. Application of neuroimaging in diagnosis of focal cortical dysplasia: a survey of computational techniques. Neurocomputing. 2024;580:127418.","journal-title":"Neurocomputing"},{"issue":"1","key":"3740_CR293","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s11689-023-09500-1","volume":"15","author":"PJ de Vries","year":"2023","unstructured":"de Vries PJ, Heunis TM, Vanclooster S, Chambers N, Bissell S, Byars AW, et al. International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND). J Neurodev Disord. 2023;15(1):32.","journal-title":"J Neurodev Disord"},{"issue":"10","key":"3740_CR294","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1164\/rccm.202209-1653OC","volume":"207","author":"YH Zhou","year":"2023","unstructured":"Zhou YH, Gallins PJ, Pace RG, Dang H, Aksit MA, Blue EE, et al. Genetic modifiers of cystic fibrosis lung disease severity: whole-genome analysis of 7,840 patients. Am J Respir Crit Care Med. 2023;207(10):1324\u201333.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3740_CR295","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13023-019-1072-y","volume":"14","author":"S Auvin","year":"2019","unstructured":"Auvin S, Bissler JJ, Cottin V, Fujimoto A, Hofbauer GFL, Jansen AC, et al. A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. Orphanet J Rare Dis. 2019;14(1):91.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3740_CR296","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ajmg.c.31653","volume":"178","author":"A Peron","year":"2018","unstructured":"Peron A, Canevini MP, Ghelma F, Di Marco F, Vignoli A. Healthcare transition from childhood to adulthood in Tuberous Sclerosis Complex. Am J Med Genet C Semin Med Genet. 2018;178(3):355\u201364.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"3740_CR297","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3389\/fneur.2019.01116","volume":"10","author":"NMP Annear","year":"2019","unstructured":"Annear NMP, Appleton RE, Bassi Z, Bhatt R, Bolton PF, Crawford P, et al. Tuberous sclerosis complex (TSC): expert recommendations for provision of coordinated care. Front Neurol. 2019;10:1116.","journal-title":"Front Neurol"},{"key":"3740_CR298","unstructured":"International Classification of Diseases code [Available from: https:\/\/www.ptenresearch.org\/for-researchers-and-professionals\/icd-code\/. Accessed on 30th Sept 2024"},{"key":"3740_CR299","unstructured":"National DIMDI project \"Kodierung von Seltenen Erkrankungen\" (Rare diseases coding) [Available from: https:\/\/www.bfarm.de\/EN\/Code-systems\/Terminologies\/Alpha-ID-SE\/national-dimdi-project\/_node.html. Accessed on 30th Sept 2024"},{"issue":"3","key":"3740_CR300","doi-asserted-by":"publisher","first-page":"rkac102","DOI":"10.1093\/rap\/rkac102","volume":"6","author":"JR Hannah","year":"2022","unstructured":"Hannah JR, Gordon PA, Galloway J, Rutter M, Peach EJ, Rooney M, et al. Validation of methods to identify people with idiopathic inflammatory myopathies using hospital episode statistics. Rheumatol Adv Pract. 2022;6(3):rkac102.","journal-title":"Rheumatol Adv Pract"},{"issue":"6","key":"3740_CR301","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/bjh.17768","volume":"194","author":"MJ Bishton","year":"2021","unstructured":"Bishton MJ, Stilwell P, Card TR, Lanyon P, Ban L, Elliss-Brookes L, et al. A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data. Br J Haematol. 2021;194(6):1039\u201344.","journal-title":"Br J Haematol"},{"issue":"12","key":"3740_CR302","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1111\/epi.17099","volume":"62","author":"DN Franz","year":"2021","unstructured":"Franz DN, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, et al. Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: results from the postextension phase of EXIST-3. Epilepsia. 2021;62(12):3029\u201341.","journal-title":"Epilepsia"},{"issue":"3","key":"3740_CR303","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat Rev Drug Discovery. 2010;9(3):203\u201314.","journal-title":"Nat Rev Drug Discovery"},{"issue":"12","key":"3740_CR304","doi-asserted-by":"publisher","first-page":"e1008489","DOI":"10.1371\/journal.pgen.1008489","volume":"15","author":"EA King","year":"2019","unstructured":"King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLOS Genet. 2019;15(12):e1008489.","journal-title":"PLOS Genet"},{"issue":"1","key":"3740_CR305","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13023-018-0836-0","volume":"13","author":"MC Jensen-van-der Weide","year":"2018","unstructured":"Jensen-van-der Weide MC, Gaasterland CMW, Roes KCB, Pontes C, Vives R, Sancho A, et al. Rare disease registries: potential applications towards impact on development of new drug treatments. Orphanet J Rare Dis. 2018;13(1):154.","journal-title":"Orphanet J Rare Dis"},{"key":"3740_CR306","unstructured":"Agency EM. Orphan Medicines in the EU 2023-02 ema.europa.eu: European Medicines Agency; 2024 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/infographic-orphan-medicines-eu_en.pdf"},{"key":"3740_CR307","unstructured":"Hayes H, Buckland S, Tarpey M. Briefing notes for researchers: public involvement in NHS, public health and social care research. Eastleigh: INVOLVE. 2012."},{"issue":"5","key":"3740_CR308","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/hex.12090","volume":"18","author":"ND Shippee","year":"2015","unstructured":"Shippee ND, Domecq Garces JP, Prutsky Lopez GJ, Wang Z, Elraiyah TA, Nabhan M, et al. Patient and service user engagement in research: a systematic review and synthesized framework. Health Expect. 2015;18(5):1151\u201366.","journal-title":"Health Expect"},{"issue":"1","key":"3740_CR309","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13023-022-02357-y","volume":"17","author":"G Velvin","year":"2022","unstructured":"Velvin G, Hartman T, Bathen T. Patient involvement in rare diseases research: a scoping review of the literature and mixed method evaluation of Norwegian researchers\u2019 experiences and perceptions. Orphanet J Rare Dis. 2022;17(1):212.","journal-title":"Orphanet J Rare Dis"},{"key":"3740_CR310","doi-asserted-by":"publisher","first-page":"752","DOI":"10.12688\/f1000research.15162.1","volume":"7","author":"P Hoddinott","year":"2018","unstructured":"Hoddinott P, Pollock A, O\u2019Cathain A, Boyer I, Taylor J, MacDonald C, et al. How to incorporate patient and public perspectives into the design and conduct of research. F1000Research. 2018;7:752.","journal-title":"F1000Research"},{"issue":"5322","key":"3740_CR311","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1126\/science.277.5322.99","volume":"277","author":"GJ Brunn","year":"1997","unstructured":"Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science. 1997;277(5322):99\u2013101.","journal-title":"Science"},{"issue":"42","key":"3740_CR312","doi-asserted-by":"publisher","first-page":"26457","DOI":"10.1074\/jbc.272.42.26457","volume":"272","author":"K Hara","year":"1997","unstructured":"Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP, et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem. 1997;272(42):26457\u201363.","journal-title":"J Biol Chem"},{"issue":"11","key":"3740_CR313","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1101\/gad.13.11.1422","volume":"13","author":"AC Gingras","year":"1999","unstructured":"Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT, Hoekstra MF, et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev. 1999;13(11):1422\u201337.","journal-title":"Genes Dev"},{"issue":"23","key":"3740_CR314","doi-asserted-by":"publisher","first-page":"8862","DOI":"10.1128\/MCB.23.23.8862-8877.2003","volume":"23","author":"KM Hannan","year":"2003","unstructured":"Hannan KM, Brandenburger Y, Jenkins A, Sharkey K, Cavanaugh A, Rothblum L, et al. mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol. 2003;23(23):8862\u201377.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"3740_CR315","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cell.2005.10.024","volume":"123","author":"MK Holz","year":"2005","unstructured":"Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005;123(4):569\u201380.","journal-title":"Cell"},{"issue":"2","key":"3740_CR316","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74\u201388.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"3740_CR317","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","volume":"8","author":"T Porstmann","year":"2008","unstructured":"Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008;8(3):224\u201336.","journal-title":"Cell Metab"},{"issue":"11","key":"3740_CR318","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.2337\/diabetes.53.11.2748","volume":"53","author":"JE Kim","year":"2004","unstructured":"Kim JE, Chen J. regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004;53(11):2748\u201356.","journal-title":"Diabetes"},{"issue":"6","key":"3740_CR319","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.celrep.2017.04.042","volume":"19","author":"Y Park","year":"2017","unstructured":"Park Y, Reyna-Neyra A, Philippe L, Thoreen CC. mTORC1 balances cellular amino acid supply with demand for protein synthesis through post-transcriptional control of ATF4. Cell Rep. 2017;19(6):1083\u201390.","journal-title":"Cell Rep"},{"issue":"6204","key":"3740_CR320","doi-asserted-by":"publisher","first-page":"1250684","DOI":"10.1126\/science.1250684","volume":"345","author":"SC Cheng","year":"2014","unstructured":"Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345(6204):1250684.","journal-title":"Science"},{"issue":"7170","key":"3740_CR321","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nature06322","volume":"450","author":"JT Cunningham","year":"2007","unstructured":"Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puigserver P. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007;450(7170):736\u201340.","journal-title":"Nature"},{"issue":"6","key":"3740_CR322","doi-asserted-by":"publisher","first-page":"L1049","DOI":"10.1152\/ajplung.00244.2018","volume":"316","author":"R Summer","year":"2019","unstructured":"Summer R, Shaghaghi H, Schriner D, Roque W, Sales D, Cuevas-Mora K, et al. Activation of the mTORC1\/PGC-1 axis promotes mitochondrial biogenesis and induces cellular senescence in the lung epithelium. Am J Physiol Lung Cell Mol Physiol. 2019;316(6):L1049\u201360.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"3740_CR323","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13(2):132\u201341.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"3740_CR324","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1091\/mbc.e08-12-1249","volume":"20","author":"CH Jung","year":"2009","unstructured":"Jung CH, Jun CB, Ro SH, Kim YM, Otto NM, Cao J, et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell. 2009;20(7):1992\u20132003.","journal-title":"Mol Biol Cell"},{"issue":"7","key":"3740_CR325","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1091\/mbc.e08-12-1248","volume":"20","author":"N Hosokawa","year":"2009","unstructured":"Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, et al. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell. 2009;20(7):1981\u201391.","journal-title":"Mol Biol Cell"},{"issue":"2","key":"3740_CR326","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.molcel.2014.11.013","volume":"57","author":"YM Kim","year":"2015","unstructured":"Kim YM, Jung CH, Seo M, Kim EK, Park JM, Bae SS, et al. mTORC1 phosphorylates UVRAG to negatively regulate autophagosome and endosome maturation. Mol Cell. 2015;57(2):207\u201318.","journal-title":"Mol Cell"},{"issue":"6","key":"3740_CR327","doi-asserted-by":"publisher","first-page":"903","DOI":"10.4161\/auto.19653","volume":"8","author":"JA Martina","year":"2012","unstructured":"Martina JA, Chen Y, Gucek M, Puertollano R. MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB. Autophagy. 2012;8(6):903\u201314.","journal-title":"Autophagy"},{"issue":"228","key":"3740_CR328","doi-asserted-by":"publisher","first-page":"ra42","DOI":"10.1126\/scisignal.2002790","volume":"5","author":"A Roczniak-Ferguson","year":"2012","unstructured":"Roczniak-Ferguson A, Petit CS, Froehlich F, Qian S, Ky J, Angarola B, et al. The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosome homeostasis. Sci Signal. 2012;5(228):ra42.","journal-title":"Sci Signal"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03740-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03740-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03740-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:02:21Z","timestamp":1748329341000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03740-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":328,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3740"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03740-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient data were recorded as part of routine clinical practice and not as part of a research study so do not require ethical approval, apart from data in Fig.\u00a0 which was part of a study approved by the Wales REC committee REC number 22\/WA\/0326.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was given for all patient related data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SD is a UCB employee and SD receives\u00a0stock or stock options from their employment. SH has received consultancy fees and research funding from Pharming in the past. DP and JMB are members of the scientific advisory board for CoSyne.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}